Annual report 2013

Transcription

Annual report 2013

RAPPORT ANNUEL 2013
Les annexes
Sommaire
LES ÉQUIPES DE RECHERCHE
DE GUSTAVE ROUSSY _ 4
PUBLICATIONS INTERNATIONALES
DE GUSTAVE ROUSSY _ 7
LES ÉQUIPES DE RECHERCHE
DE GUSTAVE ROUSSY
Biomarqueurs prédictifs et nouvelles stratégies moléculaires en thérapeutique
anticancéreuse
Responsable : Pr Fabrice André
Unité : UMR 981 Biomarqueurs prédictifs et nouvelles stratégies moléculaires en
thérapeutique anticancéreuse
Plasticité du génome et cellule B
Responsable : Dr Saïd Aoufouchi
Unité : UMR 8200 Stabilité génétique et oncogenèse
Rôle de la traduction d’ARNm dans la présentation antigénique
Responsable : Dr Sébastien Apcher
Unité : UMR 1015 Régulation des fonctions effectrices anti-tumorales par les cellules
dendritiques et les exosomes : vers la désignation
Génétique des tumeurs
Responsable : Dr Olivier Bernard
Unité : UMR 985 Génétique des tumeurs
Signalisation, Rho GTPases et progression tumorale
Responsable : Dr Jacques Bertoglio
Unité : UMR 749 Signalisation, Rho GTPases et progression tumorale
Diversité phénotypique des tumeurs solides : rôles du microenvironnement tumoral
et des micro-ARN
Responsable : Dr Pierre Busson
Unité : UMR 8126 Signalisation, noyaux et innovations en cancérologie
Nutrition, Hormones et santé de la femme
Responsable : Dr Françoise Clavel-Chapelon
Unité : UMR 1018 Centre de recherche en épidémiologie et santé des populations Hôpital Paul Brousse
Résistance tumorale à la lyse et influence du micro-environnement
Responsable : Dr Salem Chouaib
Unité : UMR 753 Immunologie des tumeurs humaines - Interaction effecteurs
cytotoxiques - Système tumoral
Radiosensibilité Tumorale et mort cellulaire
Responsables : Pr Eric Deutsch / Dr. Jean-Luc Perfettini
Unité : UMR 1030 Radiosensibilité des tumeurs et tissus sains
Espèces réactives de l’oxygène et radiocarcinogenèse
Responsable : Dr Corinne Dupuy
04 annexes rapport annuel / Gustave Roussy 2013
Rétrovirus endogènes et éléments rétroïdes des eucaryotes supérieurs
Responsable : Dr Thierry Heidmann
Unité : UMR 8122 Rétrovirus endogènes et éléments rétroïdes des eucaryotes
supérieurs
Invasion collective et morphogénèse épithéliale
Responsable : Dr Fanny Jaulin
Polymérases translésionnelles et cancer
Responsable : Dr Patricia Kannouche
Oncogenèse et progression tumorale du mélanome
Responsable : Dr Mehdi Khaled
Apoptose, cancers et immunité
Responsable : Pr Guido Kroemer
Unité : UMR 848 Apoptose, cancers et immunité
Imagerie multimodale en cancérologie
Responsable : Dr Nathalie Lassau
Unité : UMR 8081 - IR4M Imagerie par résonance magnétique médicale et
multimodalités - UPS Orsay
Maintenance des génomes, microscopies moléculaires et bionanosciences
Responsable : Dr Éric Le Cam
Processus nucléaires et signalisation apoptotique - Innovations technologiques à
visées exploratoires et thérapeutiques
Responsable : Dr Marc Lipinski
Recombinaison / Réparation et cancer (REC)
Responsable : Bernard Lopez
Microenvironnement et auto-renouvellement des cellules souches normales et
leucémiques
Responsable : Dr Fawzia Louache
Unité : UMR 1009 Hématopoïèse normale et pathologique
Antigènes tumoraux et réactivité lymphocytaire T dans le carcinome bronchique
Responsable : Dr Fathia Mami-Chouaib
Gustave Roussy 2013 / annexes rapport annuel 05
Parcours de soins coordonné et personnalisé, Coordination pour la Mesure de la
Performance et l’Amélioration de la Qualité Hospitalière
Responsable : Pr Etienne Minvielle
Unité : UMR 750 - Equipe d’Accueil Management des Organisations de Santé (EHESP) –
CNRS Villejuif
Vectorologie et thérapeutiques anti-cancéreuses
Responsable : Dr Lluis Mir
Unité : UMR 8203 Vectorologie et thérapeutiques anti-cancéreuses
Génétique et biologie des cancers du rein
Responsable : Pr Stéphane Richard
Maladies de la réparation de l’ADN
Responsable : Dr Filippo Rosselli
Etude des protéines impliquées dans la réparation de l’ADN endommagé par
les radicaux libres générés par le métabolisme cellulaire, les médicaments ou
l’environnement
Responsable : Dr Murat Saparbaev
Hémopathies myéloïdes et lymphoïdes - Physiopathologie et recherche
translationnelle
Responsable : Pr Eric Solary
Erythropoïèse et mégacaryocytopoïèse normales et pathologiques
Responsable : Dr William Vainchenker
Epidémiologie des cancers : radiocarcinogenèse et effet iatrogène des traitements
anticancéreux
Responsable : Dr Florent de Vathaire
Unité : UMR 1018 Centre de recherche en épidémiologie et santé des populations Hôpital Paul Brousse
Immunologie des tumeurs et Immunothérapie
Responsable : Pr Laurence Zitvogel
Unité : UMR 1015 Régulation des fonctions effectrices anti-tumorales par les cellules
dendritiques et les exosomes : vers la désignation
PUBLICATIONS INTERNATIONALES
DE GUSTAVE ROUSSY
A impact factor compris entre 5 et 10 (254 publications)
[1]Pernemalm M., De Petris L., Branca R.M., Forshed J., Kanter
L., Soria J.C., Girard P., Validire P., Pawitan Y., Van Den Oord J.,
Lazar V., Paishlman S., Lewensohn R., and Lehtiö J. Quantitative
proteomics profiling of primary lung adenocarcinoma tumors
reveals functional perturbations in tumor metabolism. [2013]
Journal of Proteome Research (12) 9 : 3934-3943. Impact factor : 5.001
[2]Michels J., Vitale I., Senovilla L., Enot D.P., Garcia P., Lissa D.,
Olaussen K.A., Brenner C., Soria J.C., Castedo M., and Kroemer
G. Synergistic interaction between cisplatin and PARP inhibitors
in non-small cell lung cancer. [2013] Cell Cycle (12) 6 : 877-883.
Impact factor : 5.006
[3]Bauer M.A., Carmona-Guttiérrez D., Ruckenstuhl C., Reisenbichler
A., Megalou E.V., Eisenberg T., Magnes C., Jungwirth H., Sinner
F.M., Pieber T.R., Fröhlich K.U., Kroemer G., Tavernarakis N., and
Madeo F. Spermidine promotes mating and fertilization efficiency in model organisms. [2013] Cell Cycle (12) 2 : 346-352. Impact
factor : 5.006
[4]Boilève A., Senovilla L., Vitale I., Lissa D., Martins I., Métivier D., Van
Den Brink S., Clevers H., Galluzzi L., Castedo M., and Kroemer
G. Immunosurveillance against tetraploidization-induced colon
tumorigenesis. [2013] Cell Cycle (12) 3 : 473-479. Impact factor :
5.006
[5]Bonora M., Bononi A., De Marchi E., Giorgi C., Lebiedzinska M.,
Marchi S., Patergnani S., Rimessi A., Suski J.M., Wojtala A., Wieckowski M.R., Kroemer G., Galluzzi L., and Pinton P. Role of the c
subunit of the FO ATP synthase in mitochondrial permeability
transition. [2013] Cell Cycle (12) 4 : 674-683. Impact factor :
5.006
[6]Galluzzi L., Goubar A., Olaussen K.A., Vitale I., Senovilla L., Michels
J., Robin A., Dorvault N., Besse B., Validire P., Fouret P., Behrens
C., Wistuba I.I., Soria J.C., and Kroemer G. Prognostic value of
LIPC in non-small cell lung carcinoma. [2013] Cell Cycle (12) 4 :
647-654. Impact factor : 5.006
[7]Galluzzi L., Marsili S., Vitale I., Senovilla L., Michels J., Garcia P.,
Vacchelli E., Chatelut E., Castedo M., and Kroemer G. Vitamin
B6 metabolism influences the intracellular accumulation of
cisplatin. [2013] Cell Cycle (12) 3 : 417-421. Impact factor : 5.006
[8]Jemaa M., Galluzzi L., Kepp O., Castedo M., Rello-Varona S.,
Vitale I., and Kroemer G. Transgenerational cell fate profiling:
A method for the graphical presentation of complex cell cycle
alterations. [2013] Cell Cycle (12) 1 : 183-190. Impact factor :
5.006
[9]Lainey E., Wolfromm A., Sukkurwala A.Q., Micol J.B., Fenaux P.,
Galluzzi L., Kepp O., and Kroemer G. EGFR inhibitors exacerbate
differentiation and cell cycle arrest induced by retinoic acid and
vitamin D3 in acute myeloid leukemia cells. [2013] Cell Cycle
(12) 18 : 2978-2991. Impact factor : 5.006
[10] Spaggiari S., Kepp O., Rello-Varona S., Chaba K., Adjemian S., Pype
J., Galluzzi L., Lemaire M., and Kroemer G. Antiapoptotic activity
of argon and xenon. [2013] Cell Cycle (12) 16 : 2636-2642. Impact factor : 5.006
[11] Tuloup-Minguez V., Hamaï A., Greffard A., Nicolas V., Codogno P.,
and Botti J. Autophagy modulates cell migration and ß1 integrin
membrane recycling. [2013] Cell Cycle (12) 20 : 3317-3328.
[12] Friboulet L., Postel-Vinay S., Sourisseau T., Adam J., Stoclin A.,
Ponsonnailles F., Dorvault N., Commo F., Saulnier P., Salome-Desmoulez S., Pottier G., André F., Kroemer G., Soria
J.C., and Olaussen K.A. ERCC1 function in nuclear excision and
interstrand crosslink repair pathways is mediated exclusively by
the ERCC1-202 isoform. [2013] Cell Cycle (12) 20 : 3298-3306.
[13] Jakszyn P., Lujan-Barroso L., Agudo A., Bueno-de-Mesquita H.B.,
Molina E., Sanchez M.A.J., Fonseca-Nunes A., Siersema P.D.,
Matiello A., Tumino R., Saieva C., Pala V., Vineis P., Boutron-Ruault M.C., Racine A., Bastide N., Travis R.C., Khaw K.T., Riboli
E., Murphy N., Vergnaud A.C., Trichopoulou A., Valanou E.,
Oikonomidou E., Weiderpass E., Skeie G., Johansen D., Lindkvist
B., Johansson M., Duarte-Salles T., Freisling H., Barricarte A., Ma
Huerta J., Amiano P., Tjonneland A., Overvad K., Kuehn T., Grote
V., Boeing H., Peeters P.H.M., and Gonzalez C.A. Meat and heme
iron intake and esophageal adenocarcinoma in the European
Prospective Investigation into Cancer and Nutrition study. [2013]
International Journal of Cancer (133) 11 : 2744-2750. Impact
factor : 5.007
[14] Allen N.E., Appleby P.N., Key T.J., Bueno-de-Mesquita H.B., Ros
M.M., Kiemeney L.A.L.M., Tjonneland A., Roswall N., Overvad
K., Weikert S., Boeing H., Chang-Claude J., Teucher B., Panico
S., Sacerdote C., Tumino R., Palli D., Sieri S., Peeters P., Quiros
J.R., Jakszyn P., Molina-Montes E., Chirlaque M.D., Ardanaz E.,
Dorronsoro M., Khaw K.T., Wareham N., Ljungberg B., Hallmans
G., Ehrnström R., Ericson U., Gram I.T., Parr C.L., Trichopoulou A.,
Karapetyan T., Dilis V., Clavel-Chapelon F., Boutron-Ruault M.C.,
Fagherrazzi G., Romieu I., Gunter M.J., and Riboli E. Macronutrient
intake and risk of urothelial cell carcinoma in the European prospective investigation into cancer and nutrition. [2013] International Journal of Cancer (132) 3 : 635-644. Impact factor : 5.007
[15] Buckland G., Travier N., Cottet V., Gonzalez C.A., Lujan-Barroso
L., Agudo A., Trichopoulou A., Lagiou P., Trichopoulos D., Peeters
P.H., May A., Bueno-de-Mesquita H.B., Bvan Duijnhoven F.J., Key
T.J., Allen N., Khaw K.T., Wareham N., Romieu I., Mccormack V.,
Boutron-Ruault M., Clavel-Chapelon F., Panico S., Agnoli C., Palli
D., Tumino R., Vineis P., Amiano P., Barricarte A., Rodriguez L.,
Sanchez M.J., Chirlaque M.D., Kaaks R., Teucher B., Boeing H.,
Bergmann M.M., Overvad K., Dahm C.C., Tjonneland A., Olsen
A., Manjer J., Wirfält E., Hallmans G., Johansson I., Lund E.,
Hjartaker A., Skeie G., Vergnaud A.C., Norat T., Romaguera D.,
and Riboli E. Adherence to the mediterranean diet and risk of
breast cancer in the European prospective investigation into
cancer and nutrition cohort study. [2013] International Journal
of Cancer. Impact factor : 5.007
[16] Duell E.J., Travier N., Lujan-Barroso L., Dossus L., Boutron-Ruault
M.C., Clavel-Chapelon F., Tumino R., Masala G., Krogh V., Panico
S., Ricceri F., Luisa Redondo M., Dorronsoro M., Molina-Montes
E., Huerta J.M., Barricarte A., Khaw K.T., Wareham N.J., Allen
N.E., Travis R., Siersema P.D., Peeters P.H.M., Trichopoulou
A., Fragogeorgi E., Oikonomou E., Boeing H., Schuetze M.,
Canzian F., Lukanova A., Tjonneland A., Roswall N., Overvad K.,
Weiderpass E., Gram I.T., Lund E., Lindkvist B., Johansen D., Ye
W., Sund M., Fedirko V., Jenab M., Michaud D.S., Riboli E., and
Bueno-de-Mesquita H.B. Menstrual and reproductive factors
in women, genetic variation in CYP17A1, and pancreatic cancer
risk in the European prospective investigation into cancer and
nutrition (EPIC) cohort. [2013] International Journal of Cancer
(132) 9 : 2164-2175. Impact factor : 5.007
[17] Dumay A., Feugeas J.P., Wittmer E., Lehmann-Che J., Bertheau
P., Espié M., Plassa L.F., Cottu P., Marty M., André F., Sotiriou C.,
Pusztai L., and De Thé H. Distinct tumor protein p53 mutants
in breast cancer subgroups. [2013] International Journal of
Cancer. Impact factor : 5.007
[18] Fagherazzi G., Vilier A., Balkau B., Clavel-Chapelon F., and Ma�
gliano D.J. Anthropometrics, body shape over 12 years and risk
of cancer events in pre- and post-menopausal women. [2013]
International Journal of Cancer (133) 3 : 740-748. Impact factor :
5.007
[19] Kühn T., Kaaks R., Becker S., Eomois P.P., Clavel-Chapelon F.,
Kvaskoff M., Dossus L., Tjonneland A., Olsen A., Overvad K.,
Chang-Claude J., Lukanova A., Buijsse B., Boeing H., Trichopoulou A., Lagiou P., Bamia C., Masala G., Krogh V., Sacerdote C.,
Tumino R., Mattiello A., Buckland G., Sanchez M.J., Menendez V.,
Chirlaque M.D., Barricarte A., Bueno-de-Mesquita H.B., Van Duijnhoven F.J.B., Van Gils C.H., Bakker M.F., Weiderpass E., Skeie
G., Brustad M., Andersson A., Sund M., Wareham N., Khaw K.T.,
Travis R.C., Schmidt J.A., Rinaldi S., Romieu I., Gallo V., Murphy
N., Riboli E., and Linseisen J. Plasma 25-hydroxyvitamin D and
the risk of breast cancer in the European prospective investigation into cancer and nutrition: A nested case-control study.
[2013] International Journal of Cancer (133) 7 : 1689-1700.
[20] Ritte R., Lukanova A., Tjonneland A., Olsen A., Overvad K., Mesrine
S., Fagherazzi G., Dossus L., Teucher B., Steindorf K., Boeing
H., Aleksandrova K., Trichopoulou A., Lagiou P., Trichopoulos D.,
Palli D., Grioni S., Mattiello A., Tumino R., Sacerdote C., Quiros
J.R., Buckland G., Molina-Montes E., Chirlaque M.D., Ardanaz
E., Amiano P., Bueno-de-Mesquita B., van Duijnhoven F., Van
Gils C.H., Peeters P.H., Wareham N., Khaw K.T., Key T.J., Travis
R.C., Krum-Hansen S., Gram I.T., Lund E., Sund M., Andersson
A., Romieu I., Rinaldi S., Mccormack V., Riboli E., and Kaaks R.
Height, age at menarche and risk of hormone receptor-positive
and -negative breast cancer: A cohort study. [2013] International
Journal of Cancer. Impact factor : 5.007
[21] Rohrmann S., Linseisen J., Nöthlings U., Overvad K., Egeberg
R., Tjonneland A., Boutron-Ruault M.C., Clavel-Chapelon F.,
Cottet V., Pala V., Tumino R., Palli D., Panico S., Vineis P., Boeing
H., Pischon T., Grote V., Teucher B., Khaw K.T., Wareham N.J.,
Crowe F.L., Goufa I., Orfanos P., Trichopoulou A., Jeurnink S.M.,
Siersema P.D., Peeters P.H.M., Brustad M., Engeset D., Skeie G.,
Duell E.J., Amiano P., Barricarte A., Molina-Montes E., Rodriguez L., Tormo M.J., Sund M., Ye W., Lindkvist B., Johansen D.,
Ferrari P., Jenab M., Slimani N., Ward H., Riboli E., Norat T., and
Bueno-de-Mesquita H.B. Meat and fish consumption and risk
of pancreatic cancer: Results from the European Prospective
Investigation into Cancer and Nutrition. [2013] International
Journal of Cancer (132) 3 : 617-624. Impact factor : 5.007
[22] Schlesinger S., Aleksandrova K., Pischon T., Fedirko V., Jenab
M., Trepo E., Boffetta P., Dahm C.C., Overvad K., Tjonneland A.,
Halkjaer J., Fagherazzi G., Boutron-Ruault M.C., Carbonnel F.,
Kaaks R., Lukanova A., Boeing H., Trichopoulou A., Bamia C.,
Lagiou P., Palli D., Grioni S., Panico S., Tumino R., Vineis P., Bueno-de-Mesquita H.B., van den Berg S., Peeters P.H.M., Braaten
T., Weiderpass E., Quiros J.R., Travier N., Sanchez M.J., Navarro
C., Barricarte A., Dorronsoro M., Lindkvist B., Regner S., Werner
M., Sund M., Khaw K.T., Wareham N., Travis R.C., Norat T., Wark
P.A., Riboli E., and Nöthlings U. Abdominal obesity, weight gain
during adulthood and risk of liver and biliary tract cancer in a
European cohort. [2013] International Journal of Cancer (132)
3 : 645-657. Impact factor : 5.007
[23] Steindorf K., Ritte R., Eomois P.P., Lukanova A., Tjonneland A.,
Johnsen N.F., Overvad K., Ostergaard J.N., Clavel-Chapelon F.,
Fournier A., Dossus L., Teucher B., Rohrmann S., Boeing H.,
Wientzek A., Trichopoulou A., Karapetyan T., Trichopoulos D.,
Masala G., Berrino F., Mattiello A., Tumino R., Ricceri F., Quiros J.,
Travier N., Sanchez M.J., Navarro C., Ardanaz E., Amiano P., Bueno-de-Mesquita H., van Duijnhoven F., Monninkhof E., May A.M.,
Khaw K.T., Wareham N., Key T.J., Travis R.C., Borch K.B., Sund
M., Andersson A., Fedirko V., Rinaldi S., Romieu I., Wahrendorf J.,
Riboli E., and Kaaks R. Physical activity and risk of breast cancer
overall and by hormone receptor status: The European prospective investigation into cancer and nutrition. [2013] International
Journal of Cancer. Impact factor : 5.007
[24] Ten Hagen T.L., Seynhaeve A.L., De Wiel-Ambagtsheer G.A., De
Bruijn E.A., Van Tiel S.T., Ruegg C., Meyring M., Grell M., Goodman
S.L., and Eggermont A.M. The aVß3/aVß5 integrin inhibitor
cilengitide augments tumor response to melphalan isolated limb
perfusion in a sarcoma model. [2013] International Journal of
Cancer (132) 11 : 2694-2704. Impact factor : 5.007
[25] Zamora-Ros R., Fedirko V., Trichopoulou A., Gonzalez C.A., Bamia
C., Trepo E., Nöthlings U., Duarte-Salles T., Serafini M., Bredsdorff L., Overvad K., Tjonneland A., Halkjaer J., Fagherazzi G.,
Perquier F., Boutron-Ruault M.C., Katzke V., Lukanova A., Floegel
A., Boeing H., Lagiou P., Trichopoulos D., Saieva C., Agnoli C.,
Mattiello A., Tumino R., Sacerdote C., Bueno-de-Mesquita H.B.,
Peeters P.H.M., Weiderpass E., Engeset D., Skeie G., Argüelles
M.V., Molina-Montes E., Dorronsoro M., Tormo M.J., Ardanaz
E., Ericson U., Sonestedt E., Sund M., Landberg R., Khaw K.T.,
Wareham N.J., Crowe F.L., Riboli E., and Jenab M. Dietary flavonoid, lignan and antioxidant capacity and risk of hepatocellular
carcinoma in the European prospective investigation into cancer
and nutrition study. [2013] International Journal of Cancer (133)
10 : 2429-2443. Impact factor : 5.007
[26] Benusiglio P.R., Caron O., Consolino E., Duvillard P., Coulet F.,
Blayau M., and Malka D. Cleft lip, cleft palate, hereditary diffuse
gastric cancer and germline mutations in CDH1. [2013] International Journal of Cancer. Impact factor : 5.007
[27] Droin N., Guéry L., Benikhlef N., and Solary E. Targeting apoptosis proteins in hematological malignancies. [2013] Cancer
Letters (332) 2 : 325-334. Impact factor : 5.016
[28] Opletalova K., Bourrillon A., Yang W., Pouvelle C., Armier J., Despras
E., Martin L., Mateus C., Robert C., Kannouche P., Soufir N., and
Sarasin A. Correlation of Phenotype/Genotype in a Cohort of 23
Xeroderma Pigmentosum-Variant Patients Reveals 12 New Disease-Causing POLH Mutations. [2013] Human mutation. Impact
factor : 5.050
[29] Soltys D.T., Rocha C.R.R., Lerner L.K., de Souza T.A., Munford V.,
Cabral F., Nardo T., Stefanini M., Sarasin A., Cabral-Neto J.B., and
Menck C.F.M. Novel XPG (ERCC5) Mutations Affect DNA Repair
and Cell Survival after Ultraviolet but not Oxidative Stress.
[2013] Human mutation (34) 3 : 481-489. Impact factor : 5.050
[30] Baltar V.T., Xun W.W., Johansson M., Ferrari P., Chuang S.C.,
Relton C., Ueland P.M., Midttun O., Slimani N., Jenab M.,
Clavel-Chapelon F., Boutron-Ruault M.C., Fagherazzi G., Kaaks
R., Rohrmann S., Boeing H., Weikert C., Bueno-de-Mesquita
B., Boshuizen H., Van Gils C.H., Onland-Moret N.C., Agudo A.,
Barricarte A., Navarro C., Rodriguez L., Castano J.M.H., Larranaga N., Khaw K.T., Wareham N., Allen N.E., Crowe F., Gallo V.,
Norat T., Krogh V., Masala G., Panico S., Sacerdote C., Tumino
R., Trichopoulou A., Lagiou P., Trichopoulos D., Rasmuson T.,
Hallmans G., Roswall N., Tjonneland A., Riboli E., Brennan P., and
Vineis P. A structural equation modelling approach to explore
the role of B vitamins and immune markers in lung cancer
risk. [2013] European Journal of Epidemiology (28) 8 : 677-688.
[31] Bamia C., Lagiou P., Buckland G., Grioni S., Agnoli C., Taylor
A.J., Dahm C.C., Overvad K., Olsen A., Tjonneland A., Cottet V.,
Boutron-Ruault M.C., Morois S., Grote V., Teucher B., Boeing H.,
Buijsse B., Trichopoulos D., Adarakis G., Tumino R., Naccarati
A., Panico S., Palli D., Bueno-de-Mesquita H.B., Van Duijnhoven
F.J.B., Peeters P.H.M., Engeset D., Skeie G., Lund E., Sanchez
M.J., Barricarte A., Huerta J.M., Quiros J.R., Dorronsoro M.,
Ljuslinder I., Palmqvist R., Drake I., Key T.J., Khaw K.T., Wareham
N., Romieu I., Fedirko V., Jenab M., Romaguera D., Norat T., and
Trichopoulou A. Mediterranean diet and colorectal cancer risk:
Results from a European cohort. [2013] European Journal of
Epidemiology (28) 4 : 317-328. Impact factor : 5.147
[32] Troncose Baltar V., Johansson M., Ferrari P., Chuang S.C., Relton
C., Ueland P.M., Midttun O., Slimani N., Jenab M., Clavel-Chapelon F., Boutron-Ruault M.C., and Faghe Vineis P. A structural
equation modelling approach to explore the role of B vitamins
and immune markers in lung cancer risk. [2013] European
Journal of Epidemiology (28) 8 : 677-688. Impact factor : 5.147
[33] Ali A., Bluteau O., Messaoudi K., Palazzo A., Boukour S., Lordier
L., Lecluse Y., Rameau P., Kraus-Berthier L., Jacquet-Bescond A., Lelièvre H., Depil S., Dessen P., Solary E., Raslova H.,
Vainchenker W., Plo I., and Debili N. Thrombocytopenia induced
by the histone deacetylase inhibitor abexinostat involves
p53-dependent and-independent mechanisms. [2013] Cell
Death and Disease (4) 7. Impact factor : 5.177
[34] Habel N., Hamidouche Z., Girault I., Patino-Garcia A., Lecanda
F., Marie P.J., and Fromigué O. Zinc chelation: A metallothionein
2A’s mechanism of action involved in osteosarcoma cell death
and chemotherapy resistance. [2013] Cell Death and Disease (4)
10 : e874-e874. Impact factor : 5.177
[35] Bonichon F., Palussière J., Godbert Y., Pulido M., Descat E.,
Devillers A., Meunier C., Leboulleux S., DeBaère T., Galy-Lacour
C., Lagoarde-Segot L., and Cazeau A.L. Diagnostic accuracy of
18F-FDG PET/CT for assessing response to radiofrequency
ablation treatment in lung metastases: A multicentre prospective study. [2013] European Journal of Nuclear Medicine and
Molecular Imaging (40) 12 : 1817-1827. Impact factor : 5.217
[36] Agudo A., Bonet C., Sala N., Munoz X., Aranda N., Fonseca-Nunes
A., Clavel-Chapelon F., Boutron-Ruault M.C., Vineis P., Panico S.,
Palli D., Tumino R., Grioni S., Quiros J.R., Molina E., Navarro C.,
Barricarte A., Chamosa S., Allen N.E., Khaw K.T., Bueno-de-Mesquita H.B., Siersema P.D., Numans M.E., Trichopoulou A., Lagiou
P., Trichopoulos D., Kaaks R., Canzian F., Boeing H., Meidtner
K., Johansson M., Sund M., Manjer J., Overvad K., Tjonneland
A., Lund E., Weiderpass E., Jenab M., Fedirko V., Offerhaus G.J.,
Riboli E., Gonzalez C.A., and Jakszyn P. Hemochromatosis (HFE)
gene mutations and risk of gastric cancer in the European
Prospective Investigation into Cancer and Nutrition (EPIC) study.
[2013] Carcinogenesis (34) 6 : 1244-1250. Impact factor : 5.266
[37] Castro-Vega L.J., Jouravleva K., Liu W.Y., Martinez C., Gestraud
P., Hupé P., Servant N., Albaud B., Gentien D., Gad S., Richard
S., Bacchetti S., and Londono-Vallejo A. Telomere crisis in
kidney epithelial cells promotes the acquisition of a microRNA
signature retrieved in aggressive renal cell carcinomas. [2013]
Carcinogenesis (34) 5 : 1173-1180. Impact factor : 5.266
[38] Calaminus G., Kortmann R., Worch J., Nicholson J.C., Alapetite
C., Garrè M.L., Patte C., Ricardi U., Saran F., and Frappaz D. SIOP
CNS GCT 96: Final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with
chemotherapy followed by focal primary site irradiation for pat.
[2013] Neuro-Oncology (15) 6 : 788-796. Impact factor : 5.286
[39] Grill J., Geoerger B., Gesner L., Perek D., Leblond P., Canete A.,
Aerts I., Madero L., De Toledo Codina J.S., Verlooy J., Estlin E.,
Cisar L., Breazna A., Dorman A., Bailey S., Nicolin G., Grundy R.G.,
and Hargrave D. Phase II study of irinotecan in combination with
temozolomide (TEMIRI) in children with recurrent or refractory
medulloblastoma: A joint ITCC and SIOPE brain tumor study.
[2013] Neuro-Oncology (15) 9 : 1236-1243. Impact factor : 5.286
[40] Favier R., Feriel J., Favier M., Denoyelle F.o., and Martignetti J.A.
First successful use of eltrombopag before surgery in a child
with MYH9-related thrombocytopenia. [2013] Pediatrics (132) 3 :
e793-e795. Impact factor : 5.297
[41] Lagrange B., Martin R.Z., Droin N., Aucagne R., Paggetti J., Largeot A., Itzykson R., Solary E., Delva L., and Bastie J.N. A role for
miR-142-3p in colony-stimulating factor 1-induced monocyte
differentiation into macrophages. [2013] Biochimica et Biophysica Acta - Molecular Cell Research (1833) 8 : 1936-1946. Impact
factor : 5.297
[42] Hasmim M., Noman M.Z., Messai Y., Bordereaux D., Gros G.,
Baud V., and Chouaib S. Cutting edge: Hypoxia-induced nanog
favors the intratumoral infiltration of regulatory T cells and
macrophages via direct regulation of TGF-ß1. [2013] Journal of
Immunology (191) 12 : 5802-5806. Impact factor : 5.362
[43] Seach N., Guerri L., Le Bourhis L., Mburu Y., Cui Y., Bessoles S.,
Soudais C., and Lantz O. Double positive thymocytes select mucosal-associated invariant T cells. [2013] Journal of Immunology (191) 12 : 6002-6009. Impact factor : 5.362
[44] Albanesi M., Mancardi D.A., Macdonald L.E., Iannascoli B.,
Zitvogel L., Murphy A.J., Daëron M., Leusen J.H., and Bruhns
P. Erratum: Cutting Edge: FcgRIII (CD16) and FcgRI (CD64)
are responsible for anti-glycoprotein 75 monoclonal antibody
TA99 therapy for experimental metastatic B16 melanoma (The
Journal of Immunology (2012) 189 (5513-5517)). [2013] Journal
of Immunology (190) 3 : 1381-1381. Impact factor : 5.362
[45] Jacquier H., Marcadé G., Raffoux E., Dombret H., Woerther P.L.,
Donay J.L., Arlet G., and Cambau E. In vivo selection of a complex
mutant TEM (CMT) from an inhibitor-resistant TEM (IRT) during
ceftazidime therapy. [2013] Journal of Antimicrobial Chemotherapy (68) 12 : 2792-2796 . Impact factor : 5.439
[46] Kaguelidou F., Amiel P., Blachier A., Iliescu C., Rozé J.C., Tsimaratos M., Brandt C., Kassai-Koupai B., Jacqz-Aigrain E., Gaultier C., and Alberti C. Recruitment in pediatric clinical research
was influenced by study characteristics and pediatricians’
perceptions: A multicenter survey. [2013] Journal of Clinical
Epidemiology (66) 10 : 1151-1157. Impact factor : 5.478
[47] Thuringer D., Jego G., Wettstein G., Terrier O., Cronier L., Yousfi
N., Hébrard S., Bouchot A., Hazoumé A., Joly A.L., Gleave M.,
Rosa-Calatrava M., Solary E., and Garrido C. Extracellular HSP27
mediates angiogenesis through Toll-like receptor 3. [2013]
FASEB Journal (27) 10 : 4169-4183. Impact factor : 5.480
[48] Berrou E., Adam F., Lebret M., Fergelot P., Kauskot A., Coupry
I., Jandrot-Perrus M., Nurden A., Favier R., Rosa J.P., Goizet C.,
Nurden P., and Bryckaert M. Heterogeneity of platelet functional
alterations in patients with filamin A mutations. [2013] Arteriosclerosis, thrombosis, and vascular biology (33) 1 : e11-e18.
[49] Lopez J.J., Palazzo A., Chaabane C., Albarran L., Polidano E.,
Lebozec K., Dally S., Nurden P., Enouf J., Debili N., and Bobe R.
Crucial role for endoplasmic reticulum stress during megakaryocyte maturation. [2013] Arteriosclerosis, thrombosis, and
vascular biology (33) 12 : 2750-2758. Impact factor : 5.533
[50] Chalumeau-Lemoine L., Stoclin A., Billard V., Laplanche A.,
Raynard B., and Blot F. Flexible fiberoptic bronchoscopy and
remifentanil target-controlled infusion in ICU: a preliminary
study. [2013] Intensive Care Medicine. Impact factor : 5.544
[51] Bellesoeur A., Chalumeau-Lemoine L., and Blot F. Excavated
pneumonia: An unusual suspect. [2013] Intensive Care Medicine
(39) 7 : 1318-1319. Impact factor : 5.544
[52] Bluteau O., Langlois T., Rivera-Munoz P., Favale F., Rameau P.,
Meurice G., Dessen P., Solary E., Raslova H., Mercher T., Debili
N., and Vainchenker W. Developmental changes in human megakaryopoiesis. [2013] Journal of Thrombosis and Haemostasis
(11) 9 : 1730-1741. Impact factor : 5.550
[53] Chen Y., Boukour S., Milloud R., Favier R., Saposnik B., Schlegel
N., Nurden A., Raslova H., Vainchenker W., Balland M., Nurden P.,
and Debili N. The abnormal proplatelet formation in MYH9-related macrothrombocytopenia results from an increased
actomyosin contractility and is rescued by myosin IIA inhibition.
[2013] Journal of Thrombosis and Haemostasis (11) 12 : 21632175. Impact factor : 5.550
[54] Benusiglio P.R., Malka D., Rouleau E., Pauw A.D., Buecher B.,
Noguès C., Fourme E., Colas C., Coulet F., Warcoin M., Grandjouan S., Sezeur A., Laurent-Puig P., Molière D., Tlemsani C.,
Maria M.D., Byrde V., Delaloge S., Blayau M., and Caron O. CDH1
germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: A multicentre study. [2013] Journal
of Medical Genetics (50) 7 : 486-489. Impact factor : 5.636
[55] Bubien V., Bonnet F., Brouste V., Hoppe S., Barouk-Simonet E.,
David A., Edery P., Bottani A., Layet V., Caron O., Gilbert-Dussardier B., Delnatte C., Dugast C., Fricker J.P., Bonneau D., Sevenet
N., Longy M., and Caux F. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. [2013] Journal
of Medical Genetics (50) 4 : 255-263. Impact factor : 5.636
[56] Puntervoll H.E., Yang X.R., Vetti H.H., Bachmann I.M., Avril M.F.,
Benfodda M., Catricala C., Dalle S., Duval-Modeste A.B., Ghiorzo
P., Grammatico P., Harland M., Hayward N.K., Hu H.H., Jouary T.,
Martin-Denavit T., Ozola A., Palmer J.M., Pastorino L., Pjanova
D., Soufir S., Steine S.J., Stratigos A.J., Thomas L., Tinat J., Tsao
H., Veinalde R., Tucker M.A., Paillerets B.B., Newton-Bishop J.A.,
Goldstein A.M., Akslen L.A., and Molven
A. Melanoma prone families with CDK4 germline mutation:
Phenotypic profile and associations with MC1R variants. [2013]
Journal of Medical Genetics (50) 4 : 264-270. Impact factor :
5.636
[57] Ghiorzo P., Pastorino L., Queirolo P., Bruno W., Tibiletti M.G., Nasti
S., Andreotti V., Paillerets B.B., and Bianchi Scarra G. Prevalence
of the E318K MITF germline mutation in Italian melanoma patients: Associations with histological subtypes and family cancer
history. [2013] Pigment Cell and Melanoma Research (26) 2 :
[58] Norkowski E., Ghigna M.R., Lacroix L., Le Chevalier T., Fadel
E., Dartevelle P., Dorfmuller P., and Thomas de Montpréville V.
Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology. [2013]
Journal of thoracic oncology (8) 10 : 1265-1271. Impact factor :
5.800
[59] Ramaekers B.L.T., Joore M.A., Lueza B., Bonastre J., Mauguen A.,
Pignon J.P., Le Pechoux C., De Ruysscher D.K.M., Grutters J.P.C.,
Arriagada R., Bae K., Ball D., Baumann M., Behrendt K., Belani
C.P., Beresford J., Bishop J., Bonner J.A., Choy H., Dahlberg S.E.,
De Ruysscher D., Dische S., Fournel P., Koch R., Le Péchoux C.,
Mandrekar S.J., Mauguen A., Mornex F., Nankivell M., Nelson G.,
Parmar M.K., Paulus R., Pignon J.P., Saunders M.I., Sause W.,
Schild S.E., Turrisi A.T., and Zajusz A.
Cost Effectiveness of Modified Fractionation Radiotherapy versus Conventional Radiotherapy for Unresected Non-Small-Cell
Lung Cancer Patients. [2013] Journal of thoracic oncology (8)
10 : 1295-1307. Impact factor : 5.800
[60] Scagliotti G.V., Felip E., Besse B., von Pawel J., Mellemgaard
A., Reck M., Bosquee L., Chouaid C., Lianes-Barragan P., Paul
E.M., Ruiz-Soto R., Sigal E., Ottesen L.H., and Lechevalier T. An
Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment
of Patients with Advanced-Stage Non-Small-Cell Lung Cancer.
[2013] Journal of thoracic oncology (8) 12 : 1529-1537. Impact
factor : 5.800
[61] Bachy E., Houot R., Morschhauser F., Sonet A., Brice P., Belhadj
K., Cartron G., Audhuy B., Fermé C., Feugier P., Sebban C.,
Delwail V., Maisonneuve H., Le Gouill S., Lefort S., Brousse N.,
Foussard C., and Salles G. Long-term follow up of the FL2000
study comparing CHVP-interferon to CHVP-interferon plus
rituximab in follicular lymphoma. [2013] Haematologica (98) 7 :
1107-1114. Impact factor : 5.868
[62] Charrier S., Blundell M., Cédrone G., Louache F., Vainchenker
W., Thrasher A.J., and Galy A. Wiskott-Aldrich syndrome protein-deficient hematopoietic cells can be efficiently mobilized
by granulocyte colony-stimulating factor. [2013] Haematologica
(98) 8 : 1300-1308. Impact factor : 5.868
[63] Coman T., Bachy E., Michallet M., Socié G., Uzunov M., Bourhis
J.H., Lapusan S., Brebion A., Vigouroux S., Maury S., François
S., Huynh A., Lioure B., Yakoub-Agha I., Hermine O., Milpied N.,
Mohty M., and Rubio M.T. Lenalidomide as salvage treatment
for multiple myeloma relapsing after allogeneic hematopoietic
stem cell transplantation: A report from the French Society of
Bone Marrow and Cellular Therapy. [2013] Haematologica (98)
5 : 776-783. Impact factor : 5.868
[64] Couronné L., Scourzic L., Pilati C., Valle V.D., Duffourd Y., Solary
E., Vainchenker W., Merlio J.P., Beylot-Barry M., Damm F., Stern
M.H., Gaulard P., Lamant L., Delabesse E., Merle-Beral H.,
Nguyen-Khac F., Fontenay M., Tilly H., Bastard C., Zucman-Rossi
J., Bernard O.A., and Mercher T. STAT3 mutations identified in
human hematologic neoplasms induce myeloid malignancies in
a mouse bone marrow transplantation model. [2013] Haematologica (98) 11 : 1748-1752. Impact factor : 5.868
[65] Marcais A., Porcher R., Robin M., Mohty M., Michalet M., Blaise
D., Tabrizi R., Clement L., Ceballos P., Daguindau E., Bilger K.,
Dhedin N., Lapusan S., Bay J.O., Pautas C., Garban F., Ifrah N.,
Guillerm G., Contentin N., Bourhis J.H., Agha I.Y., Bernard M.,
Cornillon J., and Milpied N. Impact of disease status and stem
cell source on the results of reduced intensity conditioning
transplant for Hodgkin’s lymphoma: A retrospective study from
the French Society of Bone Marrow Transplantation and Cellular
Therapy (SFGM-TC). [2013] Haematologica (98) 9 : 1467-1475.
[66] Oschlies I., Lisfeld J., Lamant L., Nakazawa A., D’Amore E.S.G.,
Hansson U., Hebeda K., Simonitsch-Klupp I., Maldyk J., Müllauer
L., Tinguely M., Stücker M., LeDeley M.C., Siebert R., Reiter A.,
Brugières L., Klapper W., and Woessmann W. ALK-positive
anaplastic large cell lymphoma limited to the skin: Clinical,
histopathological and molecular analysis of 6 pediatric cases.
A report from the ALCL99 study. [2013] Haematologica (98) 1 :
[67] Ribrag V., Caballero D., Fermé C., Zucca E., Arranz R., Briones
J., Gisselbrecht C., Salles G., Gianni A.M., Gomez H., Kahatt
C., Corrado C., Szyldergemajn S., Extremera S., de Miguel B.,
Cullell-Young M., and Cavalli F. Multicenter phase II study of
plitidepsin in patients with relapsed/refractory non-Hodgkin’s
lymphoma. [2013] Haematologica (98) 3 : 357-363. Impact
factor : 5.868
[68] Van Den Neste E., Casasnovas O., André M., Touati M., Senecal
D., Edeline V., Stamatoullas A., Fornecker L., Deau B., Gastinne
T., Reman O., Gaillard I., Borel C., Brice P., and Fermé C. Classical Hodgkin’s lymphoma: The Lymphoma Study Association
guidelines for relapsed and refractory adult patients eligible
for transplant. [2013] Haematologica (98) 8 : 1185-1195. Impact
factor : 5.868
[69] Coppo P. Response to “predictors of survival in thrombotic
thrombocytopenic purpura” Haematologica. [2013] Haematologica (98) 7 : e58-e58. Impact factor : 5.868
[70] Repunte-Canonigo V., Chen J., Lefebvre C., Kawamura T., Kreifeldt M., Basson O., Roberts A.J., and Sanna P.P. MeCP2 regulates
ethanol sensitivity and intake. [2013] Addiction Biology. Impact
factor : 5.929
[71] Mittempergher L., Saghatchian M., Wolf D.M., Michiels S.,
Canisius S., Dessen P., Delaloge S., Lazar V., Benz S.C., Tursz T.,
Bernards R., and van’t Veer L.J. A gene signature for late distant
metastasis in breast cancer identifies a potential mechanism
of late recurrences. [2013] Molecular Oncology (7) 5 : 987-999.
[72] Carton E., Bellesoeur A., and Mir O. Colony-stimulating factors
for febrile neutropenia. [2013] New England Journal of Medicine
(369) 3 : 285-286. Impact factor : 54.420
[73] Ferté C., Loriot Y., Clémenson C., Commo F., Gombos A., Bibault
J.E., Fumagalli I., Hamama S., Auger N., Lahon B., Chargari
C., Calderaro J., Soria J.C., and Deutsch E. IGF-1R targeting
increases the antitumor effects of DNA-damaging agents in
SCLC model: An opportunity to increase the efficacy of standard
therapy. [2013] Molecular Cancer Therapeutics (12) 7 : 12131222. Impact factor : 6.107
[74] Albi-Feldzer A., Mouret-Fourme E., Hamouda S., Motamed C.,
Dubois P.Y., Jouanneau L., and Jayr C. A double-blind randomized trial of wound and intercostal space infiltration with
ropivacaine during breast cancer surgery: Effects on chronic
postoperative pain. [2013] Anesthesiology (118) 2 : 318-326.
[75] Kvaskoff M., Bijon A., Clavel-Chapelon F., Mesrine S., and
Boutron-Ruault M.C. Childhood and Adolescent Exposures and
the Risk of Endometriosis. [2013] Epidemiology (24) 2 : 261-269.
[76] Mahnken A.H., Pereira P.L., and DeBaère T. Interventional oncologic approaches to liver metastases. [2013] Radiology (266) 2 :
[77] Franco C.A., Blanc J., Parlakian A., Blanco R., Aspalter I.M.,
Kazakova N., Diguet N., Mylonas E., Gao-Li J., Vaahtokari A.,
Penard-Lacronique V., Fruttiger M., Rosewell I., Mericskay M.,
Gerhardt H., and Li Z. SRF selectively controls tip cell invasive
behavior in angiogenesis. [2013] Development (140) 11 : 23212333. Impact factor : 6.273
[78] Aranda F., Vacchelli E., Eggermont A., Galon J., Sautès-Fridman
C., Tartour E., Zitvogel L., Kroemer G., and Galluzzi L.
Trial Watch: Peptide vaccines in cancer therapy. [2013] Oncoimmunology (2) 12 : e26621-e26621. Impact factor : 6.283
[79] Menger L., Vacchelli E., Kepp O., Eggermont A., Tartour E.,
Zitvogel L., Kroemer G., and Galluzzi L. Trial watch: Cardiac
glycosides and cancer therapy. [2013] Oncoimmunology (2) 2.
[80] Semeraro M., Vacchelli E., Eggermont A., Galon J., Zitvogel L.,
Kroemer G., and Galluzzi L. Trial Watch: Lenalidomide-based
immunochemotherapy. [2013] Oncoimmunology (2) 11 :
e26494-e26494. Impact factor : 6.283
[81] Senovilla L., Vacchelli E., Garcia P., Eggermont A., Fridman W.H.,
Galon J., Zitvogel L., Kroemer G., and Galluzzi L. Trial watch:
DNA vaccines for cancer therapy. [2013] Oncoimmunology (2) 4.
[82] Vacchelli E., Eggermont A., Fridman C.S., Galon J., Zitvogel L.,
Kroemer G., and Galluzzi L. Trial watch: Oncolytic viruses for
cancer therapy. [2013] Oncoimmunology (2) 6. Impact factor :
6.283
[83] Vacchelli E., Eggermont A., Fridman W.H., Galon J., Tartour E.,
Zitvogel L., Kroemer G., and Galluzzi L. Trial watch : Adoptive cell
transfer for anticancer immunotherapy. [2013] Oncoimmunology (2) 5. Impact factor : 6.283
[84] Vacchelli E., Eggermont A., Fridman W.H., Galon J., Zitvoge L.,
Kroemer G., and Galluzzi L. Trial watch: Immunostimulatory
cytokines. [2013] Oncoimmunology (2) 7. Impact factor : 6.283
[85] Vacchelli E., Eggermont A., Sautès-Fridman C., Galon J., Zitvogel
L., Kroemer G., and Galluzzi L. Trial watch : Toll-like receptor
agonists for cancer therapy. [2013] Oncoimmunology (2) 8.
[86] Vacchelli E., Senovilla L., Eggermont A., Fridman W.H., Galon J.,
Zitvogel L., Kroemer G., and Galluzzi L. Trial watch: Chemotherapy with immunogenic cell death inducers. [2013] Oncoimmunology (2) 3. Impact factor : 6.283
[87] Vacchelli E., Vitale I., Eggermont A., Fridman W.H., Fuaakova
J., Cremer I., Galon J., Tartour E., Zitvogel L., Kroemer G., and
Galluzzi L. Trial Watch: Dendritic cell-based interventions for
cancer therapy. [2013] Oncoimmunology (2) 10. Impact factor :
6.283
[88] Vacchelli E., Vitale I., Tartour E., Eggermont A., Sautès-Fridman
C., Galon J., Zitvogel L., Kroemer G., and Galluzzi L. Trial Watch:
Anticancer radioimmunotherapy. [2013] Oncoimmunology (2) 9 :
e25595-e25595. Impact factor : 6.283
[89] Chaput N., Flament C., Locher C., Desbois M., Rey A., Rusakiewicz S., Poirier-Colame V., Pautier P., Le Cesne A., Soria J.C., Paci
A., Rosenzwajg M., Klatzmann D., Eggermont A., Robert C., and
Zitvogel L. Phase I clinical trial combining imatinib mesylate and
IL-2 HLA-DR+ NK cell levels correlate with disease outcome.
[2013] Oncoimmunology (2) 2 : e23080-e23080. Impact factor :
6.283
[90] Galluzzi L. and Lugli E. Cancer immunotherapy turns viral. [2013]
Oncoimmunology (2) 4 : e24802-e24802. Impact factor : 6.283
[91] Galluzzi L., Kepp O., and Kroemer G. Immunogenic cell
death in radiation therapy. [2013] Oncoimmunology (2) 10 :
e26536-e26536. Impact factor : 6.283
[92] Kroemer G., Zitvogel L., and Galluzzi L. Victories and deceptions
in tumor immunology: Stimuvax®. [2013] Oncoimmunology (2)
1 : e23687-e23687. Impact factor : 6.283
[93] Ma Y., Adjemian S., Yang H., Catani J.P.P., Hannani D., Martins I.,
Michaud M., Kepp O., Sukkurwala A.Q., Vacchelli E., Galluzzi L.,
Zitvogel L., and Kroemer G. ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor
bed after anticancer chemotherapy. [2013] Oncoimmunology (2)
6. Impact factor : 6.283
[94] Ma Y., Yamazaki T., Yang H., Kepp O., Galluzzi L., Zitvogel L.,
Smyth M.J., and Kroemer G. Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy.
[2013] Oncoimmunology (2) 6. Impact factor : 6.283
[95] Mavilio D., Galluzzi L., and Lugli E. Novel multifunctional
antibody approved for the treatment of breast cancer. [2013]
Oncoimmunology (2) 6. Impact factor : 6.283
[96] Pautier P., Locher C., Robert C., Deroussent A., Flament C., Le
Cesne A., Rey A., Bahleda R., Ribrag V., Soria J.C., Vassal G.,
Eggermont A., Zitvogel L., Chaput N., and Paci A. Phase I clinical
trial combining imatinib mesylate and IL-2 in refractory cancer
patients: IL-2 interferes with the pharmacokinetics of imatinib
mesylate. [2013] Oncoimmunology (2) 2 : e23079-e23079.
[97] Prada N., Antoni G., Commo G., Rusakiewicz S., Semeraro M.,
Boufassa F., Lambotte O., Meyer L., Lise M.G., and Zitvogel L.
Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected
patients from the ANRS SEROCO cohort. [2013] Oncoimmunology (2) 3 : e23472-e23472. Impact factor : 6.283
[98] Senovilla L., Vitale I., Martins I., Kepp O., Galluzzi L., Zitvoge L.,
Castedo M., and Kroemer G. An anticancer therapy-elicited
immunosurveillance system that eliminates tetraploid cells.
[2013] Oncoimmunology (2) 1. Impact factor : 6.283
[99] Tabbekh M., Mokrani-Hammani M., Bismuth G., and MamiChouaib F. T-cell modulatory properties of CD5 and its role in
antitumor immune responses. [2013] Oncoimmunology (2) 1.
[100] Zitvogel L., Tanchot C., Granier C., and Tartour E. Following up
tumor-specific regulatory T cells in cancer patients. [2013]
Oncoimmunology (2) 7. Impact factor : 6.283
[101] Galluzzi L. New immunotherapeutic paradigms for castration-resistant prostate cancer. [2013] Oncoimmunology (2) 8 :
e26084-e26084. Impact factor : 6.283
[102] Galluzzi L. and Lugli E. Rejuvenated T cells attack old tumors.
[2013] Oncoimmunology (2) 2 : e24103-e24103. Impact factor :
6.283
[103] Kepp O., Galluzzi L., and Kroemer G. Immune effectors required
for the therapeutic activity of vorinostat. [2013] Oncoimmunology (2) 11 : e27157-e27157. Impact factor : 6.283
[104] Kroemer G., Galluzzi L., and Zitvogel L. Immunological effects of
chemotherapy in spontaneous breast cancers. [2013] Oncoimmunology (2) 12 : e27158-e27158. Impact factor : 6.283
[105] Vacchelli E., Prada N., Kepp O., and Galluzzi L. Current trends of
anticancer immunochemotherapy. [2013] Oncoimmunology (2)
6. Impact factor : 6.283
[106] Vacchelli E., Eggermont A., Galon J., Sautès-Fridman C., Zitvogel L.,
Kroemer G., and Galluzzi L. Trial watch: Monoclonal antibodies in
cancer therapy. [2013] Oncoimmunology (2) 1. Impact factor : 6.283
[107] Dewannieux M. and Heidmann T. Endogenous retroviruses: Acquisition, amplification and taming of genome invaders. [2013]
Current Opinion in Virology (3) 6 : 646-656. Impact factor : 6.298
[108] De Martino M.C., Al Ghuzlan A., Aubert S., Assié G., Scoazec J.Y.,
Leboulleux S., Do Cao C., Libè R., Nozières C., Lombès M., Pattou
F., Borson-Chazot F., Hescot S., Mazoyer C., Young J., Borget I.,
Colao A., Pivonello R., Soria J.C., Bertherat J., Schlumberger M.,
Lacroix L., and Baudin E. Molecular screening for a personalized
treatment approach in advanced adrenocortical cancer. [2013]
Journal of Clinical Endocrinology and Metabolism (98) 10 : 40804088. Impact factor : 6.310
[109] Elowe-Gruau E., Beltrand J., Brauner R., Pinto G., Samara-Boustani D., Thalassinos C., Busiah K., Laborde K., Boddaert
N., Zerah M., Alapetite C., Grill J., Touraine P., Sainte-Rose C.,
Polak M., and Puget S. Childhood craniopharyngioma: Hypothalamus-sparing surgery decreases the risk of obesity. [2013]
Journal of Clinical Endocrinology and Metabolism (98) 6 : 23762382. Impact factor : 6.310
[110] Gimenez-Roqueplo A.P., Caumont-Prim A., Houzard C., Hignette
C., Hernigou A., Halimi P., Niccoli P., Leboulleux S., Amar L.,
Borson-Chazot F., Cardot-Bauters C., Delemer B., Chabolle F.,
Coupier I., Libè R., Peitzsch M., Peyrard S., Tenenbaum F., Plouin
P.F., Chatellier G., and Rohmer V. Imaging work-up for screening
of paraganglioma and pheochromocytoma in SDHx mutation
carriers: A multicenter prospective study from the PGL.EVA
investigators. [2013] Journal of Clinical Endocrinology and
Metabolism (98) 1 : E162-E173. Impact factor : 6.310
[111] Hescot S., Leboulleux S., Amar L., Vezzosi D., Borget I.,
Bournaud-Salinas C., De La Fouchardiere C., Libè R., Do Cao
C., Niccoli P., Tabarin A., Raingeard I., Chougnet C., Giraud S.,
Gimenez-Roqueplo A.P., Young J., Borson-Chazot F., Bertherat
J., Wemeau J.L., Bertagna X., Plouin P.F., Schlumberger M., and
Baudin E. One-year progression-free survival of therapy-naive
patients with malignant pheochromocytoma and paraganglioma. [2013] Journal of Clinical Endocrinology and Metabolism
(98) 10 : 4006-4012. Impact factor : 6.310
[112] Kerkhofs T.M., Baudin E., Terzolo M., Allolio B., Chadarevian R.,
Mueller H.H., Skogseid B., Leboulleux S., Mantero F., Haak H.R.,
and Fassnacht M. Comparison of two mitotane starting dose
regimens in patients with advanced adrenocortical carcinoma.
[2013] Journal of Clinical Endocrinology and Metabolism (98)
12 : 4759-4767. Impact factor : 6.310
[113] Massicotte M.H., Borget I., Broutin S., Baracos V.E., Leboulleux S.,
Baudin E., Paci A., Deroussent A., Schlumberger M., and Antoun
S. Body composition variation and impact of low skeletal muscle
mass in patients with advanced medullary thyroid carcinoma
treated with vandetanib: Results from a placebo-controlled
study. [2013] Journal of Clinical Endocrinology and Metabolism
(98) 6 : 2401-2408. Impact factor : 6.310
[114] Tisset H., Kamar N., Faugeron I., Roy P., Pouteil-Noble C., Klein
M., Mourad G., Drui D., Do Cao C., Leenhardt L., Allix I., Bonichon
F., Morelon E., Leboulleux S., Kelly A., Niccoli P., Toubert M.E.,
Frimat L., Vantyghem M.C., Bournaud C., Schlumberger M., and
Borson-Chazot F. Is thyroid cancer recurrence risk increased
after transplantation? [2013] Journal of Clinical Endocrinology
and Metabolism (98) 10 : 3981-3988. Impact factor : 6.310
[115] Lavialle C., Cornelis G., Dupressoir A., Esnault C., Heidmann
O., Vernochet C., and Heidmann T. Paleovirology of ‘syncytins’,
retroviral env genes exapted for a role in placentation. [2013]
Philosophical Transactions of the Royal Society B: Biological
Sciences (368) 1626. Impact factor : 6.314
[116] Robin Y.M., Penel N., Pérot G., Neuville A., Vélasco V., RanchèreVince D., Terrier P., and Coindre J.M. Transgelin is a novel marker of smooth muscle differentiation that improves diagnostic
accuracy of leiomyosarcomas: a comparative immunohistochemical reappraisal of myogenic markers in 900 soft tissue
tumors. [2013] Modern Pathology. Impact factor : 6.364
[117] Sekula P., Dunant A., Mockenhaupt M., Naldi L., Bouwes Bavinck
J.N., Halevy S., Kardaun S., Sidoroff A., Liss Y., Schumacher M.,
and Roujeau J.C. Comprehensive survival analysis of a cohort of
patients with Stevens-Johnson syndrome and toxic epidermal
necrolysis. [2013] Journal of Investigative Dermatology (133) 5 :
1197-1204. Impact factor : 6.372
[118] Bibault J.E., Fumagalli I., Ferté C., Chargari C., Soria J.C., and
Deutsch E. Personalized radiation therapy and biomarker-driven treatment strategies: A systematic review. [2013] Cancer and
Metastasis Reviews (32) 3-4 : 479-492. Impact factor : 6.449
[119] Heinemann V., Douillard J.Y., Ducreux M., and Peeters M.
Targeted therapy in metastatic colorectal cancer - An example
of personalised medicine in action. [2013] Cancer Treatment
Reviews (39) 6 : 592-601. Impact factor : 6.466
[120] Martin L.A., André F., Campone M., Bachelot T., and Jerusalem
G. MTOR inhibitors in advanced breast cancer: Ready for prime
time? [2013] Cancer Treatment Reviews (39) 7 : 742-752. Impact
factor : 6.466
[121] Bhoo-Pathy N., Uiterwaal C.S.P.M., Dik V.K., Jeurnink S.M., Bech
B.H., Overvad K., Halkjaer J., Tjonneland A., Boutron-Ruault M.,
Fagherazzi G., Racine A., Katzke V.A., Li K., Boeing H., Floegel A.,
Androulidaki A., Bamia C., Trichopoulou A., Masala G., Panico S.,
Crosignani P., Tumino R., Vineis P., Peeters P.H.M., Gavrilyuk O.,
Skeie G., Weiderpass E., Duell E.J., Argüelles M., Molina-Montes
E., Navarro C., Ardanaz E., Dorronsoro M., Lindkvist B., Wallström P., Sund M., Ye W., Khaw K., Wareham N., Key T.J., Travis
R.C., Duarte-Salles T., Freisling H., Licaj I., Gallo V., Michaud
D.S., Riboli E., and Bueno-de-Mesquita H.B. Intake of coffee,
decaffeinated coffee, or tea does not affect risk for pancreatic
cancer: Results from the european prospective investigation
into nutrition and cancer study. [2013] Clinical Gastroenterology
and Hepatology (11) 11 : 1486-1492. Impact factor : 6.534
[122] Kepp O., Menger L., Vacchelli E., Locher C., Adjemian S.,
Yamazaki T., Martins I., Sukkurwala A.Q., Michaud M., Senovilla
L., Galluzzi L., Kroemer G., and Zitvogel L. Crosstalk between ER
stress and immunogenic cell death. [2013] Cytokine and Growth
Factor Reviews (24) 4 : 311-318. Impact factor : 6.537
[123] Giron-Michel J., Azzi S., Ferrini S., Chouaib S., Camussi G., Eid
P., and Azzarone B. Interleukin-15 is a major regulator of the
cell-microenvironment interactions in human renal homeostasis. [2013] Cytokine and Growth Factor Reviews (24) 1 : 13-22.
[124] Beyer J., Albers P., Altena R., Aparicio J., Bokemeyer C., Busch
J., Cathomas R., Cavallin-Stahl E., Clarke N.W., Classen J.,
Cohn-Cedermark G., Dahl A.A., Daugaard G., De Giorgi U., De
Santis M., De Wit M., Dewit R., Dieckmann K.P., Fenner M., Fizazi
K., Flechon A., Fossa S.D., Germa Lluch J.R., Gietema J.A., Gillessen S., Giwercman A., Hartmann J.T., Heidenreich A., Hentrich
M., Honecker F., Horwich A., Huddart R.A., Kliesch S., Kollmannsberger C., Krege S., Laguna M.P., Looijenga L.H.J., Lorch
A., Lotz J.P., Mayer F., Necchi A., Nicolai N., Nuver J., Oechsle K.,
Oldenburg J., Oosterhuis J.W., Powles T., Rajpert-De Meyts E.,
Rick O., Rosti G., Salvioni R., Schrader M., Schweyer S., Sedlmayer F., Sohaib A., Souchon R., Tandstad T., Winter C., and Wittekind
C. Maintaining success, reducing treatment burden, focusing
on survivorship: Highlights from the third European Consensus
Conference on Diagnosis and Treatment of Germ-Cell Cancer.
[2013] Annals of Oncology (24) 4 : 878-888. Impact factor : 6.578
[125] Chargari C., Soria J.C., and Deutsch E. Controversies and challenges regarding the impact of radiation therapy on survival.
[126] Couraud S., Cortot A.B., Greillier L., Gounant V., Mennecier B.,
Girard N., Besse B., Brouchet L., Castelnau O., Frappé P., Ferretti
G.R., Guittet L., Khalil A., Lefebure P., Laurent F., Liebart S.,
Molinier O., Quoix E., Revel M.P., Stach B., Souquet P.J., Thomas
P., Trédanie J., Lemarié E., Zalcman G., Barlès F., and Milleron
B. From randomized trials to the clinic: Is it time to implement
individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the
french intergroup (IFCT) and the groupe d’Oncologie de langue
française. [2013] Annals of Oncology (24) 3 : 586-597. Impact
factor : 6.578
[127] Querleu D., Ray-Coquard I., Classe J.M., Aucouturier J.S., Bonnet
F., Bonnier P., Darai E., Devouassoux M., Gladieff L., Glehen
O., Haie-Meder C., Joly F., Lécuru F., Lefranc J.P., Lhommé C.,
Morice P., Salengro A., Stoeckle E., Taieb S., Zeng Z.X., and Leblanc E. Quality indicators in ovarian cancer surgery: Report from
the french society of gynecologic oncology (Société Française
d’Oncologie Gynécologique, SFOG). [2013] Annals of Oncology
(24) 11 : 2732-2739. Impact factor : 6.578
[128] Soria J.C., Mauguen A., Reck M., Sandler A.B., Saijo N., Johnson
D.H., Burcoveanu D., Fukuoka M., Besse B., and Pignon J.P.
Systematic review and meta-analysis of randomised, phase II/
III trials adding bevacizumab to platinum-based chemotherapy
as first-line treatment in patients with advanced non-small-cell
lung cancer. [2013] Annals of Oncology (24) 1 : 20-30. Impact
factor : 6.578
[129] Azim H.A., Michiels S., Zagouri F., Delaloge S., Filipits M., Namer
M., Neven P., Symmans W.F., Thompson A., André F., Loi S., and
Swanton C. Utility of prognostic genomic tests in breast cancer
practice: The impakt 2012 working group consensus statement.
[130] Besse B., Tsao L.C., Chao D.T., Fang Y., Soria J.C., Almokadem
S., and Belani C.P. Phase Ib safety and pharmacokinetic study of
volociximab, an anti-a5ß1 integrin antibody, in combination with
carboplatin and paclitaxel in advanced non-small-cell lung cancer. [2013] Annals of Oncology (24) 1 : 92-96. Impact factor : 6.578
[131] Boussemart L., Routier E., Mateus C., Opletalova K., Sebille
G., Kamsu-Kom N., Thomas M., Vagner S., Favre M., Tomasic
G., Wechsler J., Lacroix L., and Robert C. Prospective study
of cutaneous side-effects associated with the BRAF inhibitor
vemurafenib: A study of 42 patients. [2013] Annals of Oncology
(24) 6 : 1691-1697. Impact factor : 6.578
[132] Coriat R., Dhooge M., Brezault C., Chaussade S., and Mir O. Blood
pressure monitoring in patients receiving bevacizumab. [2013]
Annals of Oncology (24) 4 : 1127-1127. Impact factor : 6.578
[133] Delyon J., Mateus C., Lefeuvre D., Lanoy E., Zitvogel L., Chaput N.,
Roy S., Eggermont A.M.M., Routier E., and Robert C. Experience
in daily practice with ipilimumab for thetreatment of patients
with metastatic melanoma: Anearly increase in lymphocyte and
eosinophil countsis associated with improved survival. [2013]
[134] Deutsch E., Lemanski C., Pignon J.P., Levy A., Delarochefordiere
A., Martel-Lafay I., Rio E., Malka D., Conroy T., Miglianico L., Becouarn Y., Malekzadeh K., Paris E., Juzyna B., Ezra P., and Azria
D. Unexpected toxicity of cetuximab combined with conventional
chemoradiotherapy in patients with locally advanced anal cancer: Results of the UNICANCER ACCORD 16 phase II trial. [2013]
[135] Fedirko V., Lukanova A., Bamia C., Trichopolou A., Trepo E.,
Nöthlings U., Schlesinger S., Aleksandrova K., Boffetta P.,
Tjonneland A., Johnsen N.F., Overvad K., Fagherazzi G., Racine
A., Boutron-Ruault M.C., Grote V., Kaaks R., Boeing H., Naska
A., Adarakis G., Valanou E., Palli D., Sieri S., Tumino R., Vineis P.,
Panico S., Bueno-de-Mesquita H.B., Siersema P.D., Peeters P.H.,
Weiderpass E., Skeie G., Engeset D., Quiros J.R., Zamora-Ros R.,
Sanchez M.J., Amiano P., Huerta J.M., Barricarte A., Johansen D.,
Lindkvist B., Sund M., Werner M., Crowe F., Khaw K.T., Ferrari P.,
Romieu I., Chuang S.C., Riboli E., and Jenab M. Glycemic index,
glycemic load, dietary carbohydrate, and dietary fiber intake
and risk of liver and biliary tract cancers in s. [2013] Annals of
Oncology (24) 2 : 543-553. Impact factor : 6.578
[136] Fedirko V., Trichopolou A., Bamia C., Duarte-Salles T., Trepo E.,
Aleksandrova K., Nöthlings U., Lukanova A., Lagiou P., Boffetta P.,
Trichopoulos D., Katzke V.A., Overvad K., Tjonneland A., Hansen
L., Boutron-Ruault M.C., Fagherazzi G., Bastide N., Panico S.,
Grioni S., Vineis P., Palli D., Tumino R., Bueno-de-Mesquita H.B.,
Peeters P.H., Skeie G., Engeset D., Parr C.L., Jakszyn P., Sanchez
M.J., Barricarte A., Amiano P., Chirlaque M., Quiros J.R., Sund M.,
Werner M., Sonestedt E., Ericson U., Key T.J., Khaw K.T., Ferrari
P., Romieu I., Riboli E., and Jenab M. Consumption of fish and
meats and risk of hepatocellular carcinoma: the European Prospective Investigation into Cancer and Nutrition (EPIC). [2013]
[137] Garbay D., Maki R.G., Blay J.Y., Isambert N., Neumann S.P.,
Blay C., Zanardi E., Boudou-Rouquette P., Bozec L., Duffaud F.,
Bertucci F., and Italiano A. Advanced soft-tissue sarcoma in
elderly patients: Patterns of care and survival. [2013] Annals of
[138] Goldhirsch A., Winer E.P., Coates A.S., Gelber R.D., Piccart-Gebhart M., Thürlimann B., Senn H.J., Albain K.S., André F.,
Bergh J., Bonnefoi H., Bretel-Morales D., Burstein H., Cardoso
F., Castiglione-Gertsch M., Colleoni M., Costa A., Curigliano G.,
Davidson N.E., Leo A.D., Ejlertsen B., Forbes J.F., Gnant M.,
Goodwin P., Goss P.E., Harris J.R., Hayes D.F., Hudis C.A., Ingle
J.N., Jassem J., Jiang Z., Karlsson P., Loibl S., Morrow M., Namer
M., Osborne C.K., Partridge A.H., Penault-Llorca F., Perou C.M.,
Piccart-Gebhart M.J., Pritchard K.I., Rutgers E.J.T., Sedlmayer F.,
Semiglazov V., Shao Z.M., Smith I., Toi M., Tutt A., Untch M., Viale
G., Watanabe T., Wilcken N., and Wood W.C. Personalizing the
treatment of women with early breast cancer: Highlights of the
st gallen international expert consensus on the primary therapy
of early breast Cancer 2013. [2013] Annals of Oncology (24) 9 :
2206-2223. Impact factor : 6.578
[139] Guarneri V., Dieci M.V., Barbieri E., Piacentini F., Omarini C.,
Ficarra G., Bettelli S., and Conte P.F. Loss of HER2 positivity and
prognosis after neoadjuvant therapy in HER2-positive breast
cancer patients. [2013] Annals of Oncology (24) 12 : 2990-2994.
[140] Horwich A., Hugosson J., de reijke T., Wiegel T., Fizazi K., Kataja
V., Parker C., Bellmunt J., Berthold D., Bill-axelson A., Carlsson S., Daugaard G., De meerleer G., de reijke T., Dearnaley D.,
Fonteyne V., Gillessen S., Heinrich D., Kwiatkowski M., Nilsson S.,
Padhani A., Papandreou C., Roobol M., Sella A., Valdagni R., Van
der kwast T., and Verhagen P. Prostate cancer: ESMO consensus
conference guidelines 2012. [2013] Annals of Oncology (24) 5 :
1141-1162. Impact factor : 6.578
[141] Italiano A., Le Cesne A., Bellera C., Piperno-Neumann S., Duffaud
F., Penel N., Cassier P., Domont J., Takebe N., Kind M., Coindre
J.M., Blay J.Y., and Bui B. GDC-0449 in patients with advanced
chondrosarcomas: A French sarcoma group/US and French
national cancer institute single-arm phase ii collaborative study.
[2013] Annals of Oncology (24) 11 : 2922-2926 . Impact factor :
6.578
[142] Italiano A., Mir O., Cioffi A., Palmerini E., Piperno-Neumann S.,
Perrin C., Chaigneau L., Penel N., Duffaud F., Kurtz J.E., Collard
O., Bertucci F., Bompas E., Le Cesne A., Maki R.G., Ray I., and
Blay J.Y. Advanced chondrosarcomas: Role of chemotherapy and
survival. [2013] Annals of Oncology (24) 11 : 2916-2922. Impact
factor : 6.578
[143] Izzedine H., Escudier B., Rouvier P., Gueutin V., Varga A., Bahleda
R., and Soria J.C. Acute tubular necrosis associated with mTOR
inhibitor therapy: A real entity biopsy-proven. [2013] Annals of
[144] Ketterer N., Coiffier B., Thieblemont C., Fermé C., Brière J.,
Casasnovas O., Bologna S., Christian B., Connerotte T., Récher C.,
Bordessoule D., Fruchart C., Delarue R., Bonnet C., Morschhauser F., Anglaret B., Soussain C., Fabiani B., Tilly H., and Haioun
C. Phase III study of ACVBP versus ACVBP plus rituximab for
patients with localized low-risk diffuse large B-cell lymphoma
(LNH03-1b). [2013] Annals of Oncology (24) 4 : 1032-1037.
[145] Le Péchoux C., Musat E., Baey C., Al Mokhles H., Terrier P.,
Domont J., Le Cesne A., Laplanche A., and Bonvalot S. Should
adjuvant radiotherapy be administered in addition to front-line
aggressive surgery (FAS) in patients with primary retroperitoneal sarcoma? [2013] Annals of Oncology (24) 3 : 832-837.
[146] Ligthart S.T., Bidard F.C., Decraene C., Bachelot T., Delaloge
S., Brain E., Campone M., Viens P., Pierga J.Y., and Terstappen
L.W.M.M. Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and
non-metastatic breast cancer. [2013] Annals of Oncology (24) 5 :
1231-1238. Impact factor : 6.578
[147] Loriot Y., Bianchini D., Ileana E., Sandhu S., Patrikidou A., Pezaro
C., Albiges L., Attard G., Fizazi K., De Bono J.S., and Massard C.
Antitumour activity of abiraterone acetate against metastatic
castration-resistant prostate cancer progressing after docetaxel
and enzalutamide (MDV3100). [2013] Annals of Oncology (24) 7 :
1807-1812. Impact factor : 6.578
[148] Macaulay V.M., Middleton M.R., Protheroe A.S., Tolcher A., Dieras
V., Sessa C., Bahleda R., Blay J.Y., LoRusso P., Mery-Mignard D.,
and Soria J.C. Phase I study of humanized monoclonal antibody
AVE1642 directed against the type 1 insulin-like growth factor
receptor (IGF-1R), administered in combination with anticancer
therapies to patients with advanced solid tumors. [2013] Annals
of Oncology (24) 3 : 784-791. Impact factor : 6.578
[149] Massard C., Kramar A., Beyer J., Hartmann J.T., Lorch A., Pico
J.L., Rosti G., Droz J.P., and Fizazi K. Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors. [2013] Annals of Oncology (24) 2 :
[150] Obon-Santacana M., Slimani N., Lujan-Barroso L., Travier N.,
Hallmans G., Freisling H., Ferrari P., Boutron-Ruault M.C., Racine
A., Clavel F., Saieva C., Pala V., Tumino R., Mattiello A., Vineis P.,
Argüelles M., Ardanaz E., Amiano P., Navarro C., Sanchez M.J.,
Molina Montes E., Key T., Khaw K.T., Wareham N., Peeters P.H.,
Trichopoulou A., Bamia C., Trichopoulos D., Boeing H., Kaaks
R., Katzke V., Ye W., Sund M., Ericson U., Wirfält E., Overvad K.,
Tjonneland A., Olsen A., Skeie G., Asli L.A., Weiderpass E., Riboli
E., Bueno-de-Mesquita H.B., and Duell E.J. Dietary intake of
acrylamide and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. [2013]
[151] Patrikidou A., Chabaud S., Ray-Coquard I., Bui B.N., Adenis A.,
Rios M., Bertucci F., Duffaud F., Chevreau C., Cupissol D., Domont
J., Pérol D., Blay J.Y., and Le Cesne A. Influence of imatinib
interruption and rechallenge on the residual disease in patients
with advanced GIST: Results of the BFR14 prospective french
sarcoma group randomised, phase III trial. [2013] Annals of
[152] Pautier P., Floquet A., Gladieff L., Bompas E., Ray-Coquard I.,
Piperno-Neumann S., Selle F., Guillemet C., Weber B., Largillier
R., Bertucci F., Opinel P., Duffaud F., Reynaud-Bougnoux A.,
Delcambre C., Isambert N., Kerbrat P., Netter-Pinon G., Pinto N.,
Duvillard P., Haie-Meder C., Lhommé C., and Rey A. A randomized clinical trial of adjuvant chemotherapy with doxorubicin,
ifosfamide, and cisplatin followed by radiotherapy versus
radiotherapy alone in patients with localized uterine sarcomas
(SARCGYN study). A study of the French Sarcoma Group. [2013]
[153] Pécuchet N., Bigot F., Gachet J., Massard C., Albiges L., Teghom
C., Allory Y., Méjean A., Escudier B., and Oudard S. Triple
combination of bevacizumab, gemcitabine and platinum salt in
metastatic collecting duct carcinoma. [2013] Annals of Oncology
(24) 12 : 2963-2967. Impact factor : 6.578
[154] Penel N., Demetri G.D., Blay J.Y., Cousin S., Maki R.G., Chawla
S.P., Judson I., Von Mehren M., Schöffski P., Verweij J., Casali P.,
Rodenhuis S., Schütte H.J., Cassar A., Gomez J., Nieto A., Zintl P.,
Pontes M.J., and Le Cesne A. Growth modulation index as metric
of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. [2013]
[155] Pierga J.Y., Bidard F.C., Cropet C., Tresca P., Dalenc F., Romieu
G., Campone M., Aït-Oukhatar C.M., Rhun E.L., Gonçalves A.,
Leheurteur M., Dômont J., Gutierrez M., Curé H., Ferrero J.M.,
Labbe-Devilliers C., and Bachelot T. Circulating tumor cells and
brain metastasis outcome in patients with HER2-positive breast
cancer: The LANDSCAPE trial. [2013] Annals of Oncology (24)
12 : 2999-3004. Impact factor : 6.578
[156] Rodrigues M.J., Peron J., Frénel J.S., Vano Y.A., Wassermann J.,
Debled M., Picaud F., Albiges L., Vincent-Salomon A., and Cottu
P.H. Benefit of adjuvant trastuzumab-based chemotherapy in
T1ab node-negative HER2-overexpressing breast carcinomas: A
multicenter retrospective series. [2013] Annals of Oncology (24)
4 : 916-924. Impact factor : 6.578
[157] Schlesinger S., Aleksandrova K., Pischon T., Jenab M., Fedirko V.,
Trepo E., Overvad K., Roswall N., Tjonneland A., Boutron-Ruault
M.C., Fagherazzi G., Racine A., Kaaks R., Grote V.A., Boeing H.,
Trichopoulou A., Pantzalis M., Kritikou M., Mattiello A., Sieri S.,
Sacerdote C., Palli D., Tumino R., Peeters P.H., Bueno-de-Mesquita H.B., Weiderpass E., Quiros J.R., Zamora-Ros R., Sanchez
M.J., Arriola L., Ardanaz E., Tormo M.J., Nilsson P., Lindkvist B.,
Sund M., Rolandsson O., Khaw K.T., Wareham N., Travis R.C.,
Riboli E., and Nothlings U. Diabetes mellitus, insulin treatment,
diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort. [2013] Annals of Oncology
(24) 9 : 2449-2455. Impact factor : 6.578
[158] Sternberg C.N., Molina A., North S., Mainwaring P., Fizazi K., Hao
Y., Rothman M., Gagnon D.D., Kheoh T., Haqq C.M., Cleeland C.,
De Bono J.S., and Scher H.I. Effect of abiraterone acetate on
fatigue in patients with metastatic castration-resistant prostate
cancer after docetaxel chemotherapy. [2013] Annals of Oncology
(24) 4 : 1017-1025. Impact factor : 6.578
[159] Thariat J., Schouman T., Brouchet A., Sarini J., Miller R.C.,
Reychler H., Ray-Coquard I., Italiano A., Verite C., Sohawon S.,
Bompas E., Dassonville O., Salas S., Aldabbagh K., Maingon P.,
de la MotteRouge T., Kurtz J.E., Usseglio J., Kerbrat P., Raoul G.,
Lotz J.P., Bar-Sela G., Brugières L., Chaigneau L., Saada E., Odin
G., Marcy P.Y., Thyss A., and Julieron M. Osteosarcomas of the
mandible: Multidisciplinary management of a rare tumor of the
young adult a cooperative study of the GSF-GETO, rare cancer
network, GETTEC/refcor and sfce. [2013] Annals of Oncology
(24) 3 : 824-831. Impact factor : 6.578
[160] Postel-Vinay S., Schlumberger M., and Soria J.C. Tumour markers fluctuations in patients with medullary thyroid carcinoma
receiving long-term RET inhibitor therapy: Ordinary lapping or
alarming waves foreshadowing disease progression? [2013]
[161] Sola B., Poirot M., De Medina P., Bustany S., Marsaud V.,
Silvente-Poirot S., and Renoir J.M. Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through
alteration of cholesterol metabolism. [2013] Oncotarget (4) 6 :
[162] Thevenon J., Bourredjem A., Faivre L., Cardot-Bauters C., Calender A., Murat A., Giraud S., Niccoli P., Odou M.F., Borson-Chazot
F., Barlier A., Lombard-Bohas C., Clauser E., Tabarin A., Parfait
B., Chabre O., Castermans E., Beckers A., Ruszniewski P., Le
bras M., Delemer B., Bouchard P., Guilhem I., Rohmer V., Goichot
B., Caron P., Baudin E., Chanson P., Groussin L., Du boullay H.,
Weryha G., Lecomte P., Penfornis A., Bihan H., Archambeaud F.,
Kerlan V., Duron F., Kuhn J., Vergas B., Rodier M., Renard M.,
Sadoul J., Binquet C., and Goudet P. Higher risk of death among
men1 patients with mutations in the jund interacting domain:
A groupe d’étude des tumeurs endocrines (GTE) cohort study.
[2013] Human Molecular Genetics (22) 10 : 1940-1948. Impact
factor : 6.677
[163] Romaguera D., Norat T., Wark P.A., Vergnaud A.C., Schulze M.B.,
van Woudenbergh G.J., Drogan D., Amiano P., Molina-Montes
E., Sanchez M.J., Balkau B., Barricarte A., Beulens J.W.J., Clavel-Chapelon F., Crispim S.P., Fagherazzi G., Franks P.W., Grote
V.A., Huybrechts I., Kaaks R., Key T.J., Khaw K.T., Nilsson P., Overvad K., Palli D., Panico S., Quiros J.R., Rolandsson O., Sacerdote
C., Sieri S., Slimani N., Spijkerman A.M.W., Tjonneland A., Tormo
M.J., Tumino R., van den Berg S.W., Wermeling P.R., Zamora-Ros
R., Feskens E.J.M., Langenberg C., Sharp S.J., Forouhi N.G.,
Riboli E., and Wareham N.J. Consumption of sweet beverages
and type 2 diabetes incidence in European adults: results from
EPIC-InterAct. [2013] Diabetologia (56) 7 : 1520-1530. Impact
factor : 6.880
[164] Fagherazzi G., Vilier A., Saes Sartorelli D., Lajous M., Balkau
B., and Clavel-Chapelon F. Consumption of artificially and
sugar-sweetened beverages and incident type 2 diabetes in the
Etude Epidemiologique aupres des femmes de la Mutuelle Generale de l’Education Nationale-European Prospective Investigation into Cancer and Nutrition cohort. [2013] American journal
of clinical nutrition (97) 3 : 517-523. Impact factor : 6.918
[165] Ferrari P., Rinaldi S., Jenab M., Lukanova A., Olsen A., Tjonneland
A., Overvad K., Clavel-Chapelon F., Fagherazzi G., Touillaud M.,
Kaaks R., Von Rüsten A., Boeing H., Trichopoulou A., Lagiou P.,
Benetou V., Grioni S., Panico S., Masala G., Tumino R., Polidoro
S., Bakker M.F., Van Gils C.H., Ros M.M., Bueno-de-Mesquita
H.B., Krum-Hansen S., Engeset D., Skeie G., Pilar A., Sanchez
M.J., Buckland G., Ardanaz E., Chirlaque D., Rodriguez L., Travis
R., Key T., Khaw K.T., Wareham N.J., Sund M., Lenner P., Slimani
N., Norat T., Aune D., Riboli E., and Romieu I. Dietary fiber intake
and risk of hormonal receptor-defined breast cancer in the European prospective investigation into cancer and nutrition study.
[2013] American journal of clinical nutrition (97) 2 : 344-353.
[166] Prado C.M., Sawyer M.B., Ghosh S., Lieffers J.R., Esfandiari N.,
Antoun S., and Baracos V.E. Central tenet of cancer cachexia
therapy: Do patients with advanced cancer have exploitable
anabolic potential? [2013] American journal of clinical nutrition
(98) 4 : 1012-1019. Impact factor : 6.918
[167] Vergnaud A.C., Romaguera D., Peeters P.H., Van Gils C.H., Chan
D.S.M., Romieu I., Freisling H., Ferrari P., Clavel-Chapelon F.,
Fagherazzi G., Dartois L., Li K., Tikk K., Bergmann M.M., Boeing
H., Tjonneland A., Olsen A., Overvad K., Dahm C.C., Redondo
M.L., Agudo A., Sanchez M.J., Amiano P., Chirlaque M.D., Ardanaz
E., Khaw K.T., Wareham N.J., Crowe F., Trichopoulou A., Orfanos
P., Trichopoulos D., Masala G., Sieri S., Tumino R., Vineis P.,
Panico S., Bueno-de-Mesquita H.B., Ros M.M., May A., Wirfalt
E., Sonestedt E., Johansson I., Hallmans G., Lund E., Weiderpass
E., Parr C.L., Riboli E., and Norat T. Adherence to the World
Cancer Research Fund/American Institute for Cancer Research
guidelines and risk of death in Europe: Results from the European Prospective Investigation into Nutrition and Cancer cohort
study1-5. [2013] American journal of clinical nutrition (97) 5 :
1107-1120. Impact factor : 6.918
[168] Fagherazzi G. and Clavel-Chapelon F. Reply to HC Stevens and
C La Vecchia : Artificially and sugar-sweetened beverages and
incident type 2 diabetes. [2013] American journal of clinical
nutrition (98) 1 : 250-251. Impact factor : 6.918
[169] Goéré D., Benhaim L., Bonnet S., Malka D., Faron M., Elias D.,
Lefèvre J.H., Deschamps F., Dromain C., Boige V., Dumont F., de
Baere T., and Ducreux M. Adjuvant chemotherapy after resection
of colorectal liver metastases in patients at high risk of hepatic
recurrence: A comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy. [2013]
Annals of Surgery (257) 1 : 114-120. Impact factor : 7.188
[170] Goéré D., Malka D., Tzanis D., Gava V., Boige V., Eveno C., Maggiori L., Dumont F., Ducreux M., and Elias D. Is there a possibility
of a cure in patients with colorectal peritoneal carcinomatosis
amenable to complete cytoreductive surgery and intraperitoneal
chemotherapy? [2013] Annals of Surgery (257) 6 : 1065-1071.
[171] Maggiori L., Goéré D., Viana B., Tzanis D., Dumont F., Honoré C.,
Eveno C., and Elias D. Should patients with peritoneal carcinomatosis of colorectal origin with synchronous liver metastases
be treated with a curative intent?: A case-control study. [2013]
Annals of Surgery (258) 1 : 116-121. Impact factor : 7.188
[172] Grabarz A., Guirouilh-Barbat J., Barascu A., Pennarun G., Genet
D., Rass E., Germann S.M., Bertrand P., Hickson I.D., and Lopez
B.S. A Role for BLM in Double-Strand Break Repair Pathway
Choice: Prevention of CtIP/Mre11-Mediated Alternative Nonhomologous End-Joining. [2013] Cell Reports (5) 1 : 21-28. Impact
factor : 7.207
[173] Le Bihan Y.V., Matot B., Pietrement O., Giraud-Panis M.J.,
Gasparini S., Le Cam E., Gilson E., Sclavi B., Miron S., and Le Du
M.H. Effect of Rap1 binding on DNA distortion and potassium
permanganate hypersensitivity. [2013] Acta crystallographica.
Section D, Biological crystallography (69) Pt 3 : 409-419. Impact
factor : 7.232
[174] Li L., Ten Hagen T.L.M., Bolkestein M., Gasselhuber A., Yatvin J.,
Van Rhoon G.C., Eggermont A.M.M., Haemmerich D., and Koning
G.A. Improved intratumoral nanoparticle extravasation and
penetration by mild hyperthermia. [2013] Journal of Controlled
Release (167) 2 : 130-137. Impact factor : 7.261
[175] Li L., Ten Hagen T.L.M., Hossann M., Süss R., Van Rhoon G.C.,
Eggermont A.M.M., Haemmerich D., and Koning G.A. Mild hyperthermia triggered doxorubicin release from optimized stealth
thermosensitive liposomes improves intratumoral drug delivery
and efficacy. [2013] Journal of Controlled Release (168) 2 : 142150. Impact factor : 7.261
[176] Rohrmann S., Overvad K., Bueno-de-Mesquita H.B., Jakobsen
M.U., Egeberg R., Tjonneland A., Nailler L., Boutron-Ruault
M.C., Clavel-Chapelon F., Krogh V., Palli D., Panico S., Tumino R.,
Ricceri F., Bergmann M.M., Boeing H., Li K., Kaaks R., Khaw K.T.,
Wareham N.J., Crowe F.L., Key T.J., Naska A., Trichopoulou A.,
Trichopoulos D., Leenders M., Peeters P.H.M., Engeset D., Parr
C.L., Skeie G., Jakszyn P., Sanchez M.J., Huerta J.M., Redondo
M.L., Barricarte A., Amiano P., Drake I., Sonestedt E., Hallmans
G., Johansson I., Fedirko V., Romieux I., Ferrari P., Norat T.,
Vergnaud A.C., Riboli E., and Linseisen A.J. Meat consumption
and mortality - results from the European Prospective Investigation into Cancer and Nutrition. [2013] BMC Medicine (11) 1.
[177] Micha R., Michas G., Lajous M., and Mozaffarian D. Processing of
meats and cardiovascular risk: Time to focus on preservatives.
[2013] BMC Medicine (11) 1. Impact factor : 7.276
[178] Chung G.T.Y., Lung R.W.M., Hui A.B.Y., Yip K.Y.L., Woo J.K.S., Chow
C., Tong C.Y.K., Lee S.D., Yuen J.W.F., Lun S.W.M., Tso K.K.Y.,
Wong N., Tsao S.W., Yip T.T.C., Busson P., Kim H., Seo J.S., O’Sullivan B., Liu F.F., To K.F., and Lo K.W. Identification of a recurrent
transforming UBR5-ZNF423 fusion gene in EBV-associated
nasopharyngeal carcinoma. [2013] Journal of Pathology (231) 2 :
[179] Chung G.T.Y., Lou W.P.K., Chow C., To K.F., Choy K.W., Leung
A.W.C., Tong C.Y.K., Yuen J.W.F., Ko C.W., Yip T.T.C., Busson P.,
and Lo K.W. Constitutive activation of distinct NF-kB signals in
EBV-associated nasopharyngeal carcinoma. [2013] Journal of
Pathology (231) 3 : 311-322 . Impact factor : 7.330
[180] Berois N., Gattolliat C.H., Barrios E., Capandeguy L., Douc-Rasy
S., Valteau-Couanet D., Bénard J., and Osinaga E. GALNT9 gene
expression is a prognostic marker in neuroblastoma patients.
[2013] Clinical Chemistry (59) 1 : 225-233. Impact factor : 7.768
[181] Laforge M., Limou S., Harper F., Casartelli N., Rodrigues V., Silvestre R., Haloui H., Zagury J.F., Senik A., and Estaquier J. DRAM
Triggers Lysosomal Membrane Permeabilization and Cell Death
in CD4+ T Cells Infected with HIV. [2013] PLoS Pathogens (9) 5 :
e1003328-e1003328. Impact factor : 8.057
[182] Laurenceau R., Péhau-Arnaudet G., Baconnais S., Gault J.,
Malosse C., Dujeancourt A., Campo N., Chamot-Rooke J., Le
Cam E., Claverys J.P., and Fronzes R. A Type IV Pilus Mediates
DNA Binding during Natural Transformation in Streptococcus
pneumoniae. [2013] PLoS Pathogens (9) 6 . Impact factor : 8.057
[183] Le Bourhis L., Dusseaux M., Bohineust A., Bessoles S., Martin E.,
Premel V., Core M., Sleurs D., Serriari N.E., Treiner E., Hivroz C.,
Sansonetti P., Gougeon M.L., Soudais C., and Lantz O. MAIT Cells
Detect and Efficiently Lyse Bacterially-Infected Epithelial Cells.
[2013] PLoS Pathogens (9) 10. Impact factor : 8.057
[184] Couch F.J., Wang X., McGuffog L., Lee A., Olswold C., Kuchenbaecker K.B., Soucy P., Fredericksen Z., Barrowdale D., Dennis
J., Gaudet M.M., Dicks E., Kosel M., Healey S., Sinilnikova O.M.,
Bacot F., Vincent D., Hogervorst F.B.L., Peock S., Stoppa-Lyonnet
D., Jakubowska A., Radice P., Schmutzler R.K., Domchek S.M.,
Piedmonte M., Singer C.F., Friedman E., Thomassen M., Hansen
T.V.O., Neuhausen S.L., Szabo C.I., Blanco I., Greene M.H., Karlan
B.Y., Garber J., Phelan C.M., Weitzel J.N., Montagna M., Olah
E., Andrulis I.L., Godwin A.K., Yannoukakos D., Goldgar D.E.,
Caldes T., Nevanlinna H., Osorio A., Terry M.B., Daly M.B., van
Rensburg E.J., Hamann U., Ramus S.J., Ewart Toland A., Caligo
M.A., Olopade O.I., Tung N., Claes K., Beattie M.S., Southey M.C.,
Imyanitov E.N., Tischkowitz M., Janavicius R., John E.M., Kwong
A., Diez O., Balmano J., Barkardottir R.B., Arun B.K., Rennert G.,
Teo S.H., Ganz P.A., Campbell I., van der Hout A.H., van Deurzen
C.H.M., Seynaeve C., Gomez-Garcia E.B., van Leeuwen F.E.,
Meijers-Heijboer H.E.J., Gille J.J.P., Ausems M.G.E.M., Blok M.J.,
Ligtenberg M.J.L., Rookus M.A., Devilee P., Verhoef S., van Os
T.A.M., Wijnen J.T., Frost D., Ellis S., Fineberg E., Platte R., Evans
D.G., Izatt L., Eeles R.A., Adlard J., Eccles D.M., Cook J., Brewer
C., Douglas F., Hodgson S., Morrison P.J., Side L.E., Donaldson
A., Houghton C., Rogers M.T., Dorkins H., Eason J., Gregory H.,
McCann E., Murray A., Calender A., Hardouin A., Berthet P., Delnatte C., Nogues C., Lasset C., Houdayer C., Leroux D., Rouleau
E., Prieur F., Damiola F., Sobol H., Coupier I., Venat-Bouvet L.,
Castera L., Gauthier-Villars M., Léoné M., Pujol P., Mazoyer S.,
Bignon Y.J., Zlowocka-Perlowska E., Gronwald J., Lubinski J.,
Durda K., Jaworska K., Huzarski T., Spurdle A.B., Viel A., Peissel
B., Bonanni B., Melloni G., Ottini L., Papi L., Varesco L., Tibiletti
M.G., Peterlongo P., Volorio S., Manoukian S., Pensotti V., Arnold
N., Engel C., Deissler H., Gadzicki D., Gehrig A., Kast K., Rhiem
K., Meindl A., Niederacher D., Ditsch N., Plendl H., Preisler-Adams S., Engert S., Sutter C., Varon-Mateeva R., Wappenschmidt
B., Weber B.H.F., Arver B., Stenmark-Askmalm M., Loman N.,
Rosenquist R., Einbeigi Z., Nathanson K.L., Rebbeck T.R., Blank
S.V., Cohn D.E., Rodriguez G.C., Small L., Friedlander M., BaeJump V.L., Fink-Retter A., Rappaport C., Gschwantler-Kaulich D.,
Pfeiler G., Tea M.K., Lindor N.M., Kaufman B., Shimon Paluch S.,
Laitman Y., Skytte A.B., Gerdes A.M., Pedersen I.S., Moeller S.T.,
Kruse T.A., Jensen U.B., Vijai J., Sarrel K., Robson M., Kauff N.,
Mulligan A.M., Glendon G., Ozcelik H., Ejlertsen B., Nielsen F.C.,
Jonson L., Andersen M.K., Ding Y.C., Steele L., Foretova L., Teulé
A., Lazaro C., Brunet J., Pujana M.A., Mai P.L., Loud J.T., Walsh C.,
Lester J., Orsulic S., Narod S.A., Herzog J., Sand S.R., Tognazzo
S., Agata S., Vaszko T., Weaver J., Stavropoulou A.V., Buys S.S.,
Romero A., de la Hoya M., Aittomäki K., Muranen T.A., Duran M.,
Chung W.K., Lasa A., Dorfling C.M., Miron A., Benitez J., Senter
L., Huo D., Chan S.B., Sokolenko A.P., Chiquette J., Tihomirova
L., Friebel T.M., Agnarsson B.A., Lu K.H., Lejbkowicz F., James
P.A., Hall P., Dunning A.M., Tessier D., Cunningham J., Slager
S.L., Wang C., Hart S., Stevens K., and Simard J. Genome-Wide
Association Study in BRCA1 Mutation Carriers Identifies Novel
Loci Associated with Breast and Ovarian Cancer Risk. [2013]
PLoS Genetics (9) 3 : e1003212-e1003212. Impact factor : 8.167
[185] Esnault C., Cornelis G., Heidmann O., and Heidmann T. Differential Evolutionary Fate of an Ancestral Primate Endogenous Retrovirus Envelope Gene, the EnvV Syncytin, Captured
for a Function in Placentation. [2013] PLoS Genetics (9) 3 :
e1003400-e1003400. Impact factor : 8.167
[186] Esta A., Ma E., Dupaigne P., Maloisel L., Guerois R., Le Cam
E., Veaute X., and Coïc E. Rad52 Sumoylation Prevents the
Toxicity of Unproductive Rad51 Filaments Independently of
the Anti-Recombinase Srs2. [2013] PLoS Genetics (9) 10 :
e1003833-e1003833. Impact factor : 8.167
[187] Gaudet M.M., Kuchenbaecker K.B., Vijai J., Klein R.J., Kirchhoff
T., McGuffog L., Barrowdale D., Dunning A.M., Lee A., Dennis
J., Healey S., Dicks E., Soucy P., Sinilnikova O.M., Pankratz
V.S., Wang X., Eldridge R.C., Tessier D.C., Vincent D., Bacot F.,
Hogervorst F.B.L., Peock S., Stoppa-Lyonnet D., Coulet F., Colas
C., Soubrier F., Peterlongo P., Schmutzler R.K., Nathanson
K.L., Piedmonte M., Singer C.F., Thomassen M., Sokolowska J.,
Bronner M., Hansen T.V.O., Neuhausen S.L., Blanco I., Greene
M.H., Garber J., Weitzel J.N., Andrulis I.L., Goldgar D.E., D’Andrea
E., Caldes T., Nevanlinna H., Osorio A., van Rensburg E.J., Arason
A., Rennert G., van den Ouweland A.M.W., van der Hout A.H.,
Kets C.M., Aalfs C.M., Wijnen J.T., Ausems M.G.E.M., Frost D.,
Ellis S., Fineberg E., Platte R., Evans D.G., Jacobs C., Adlard J.,
Tischkowitz M., Porteous M.E., Damiola F., Golmard L., Barjhoux
L., Longy M., Belotti M., Ferrer S.F., Mazoyer S., Spurdle A.B.,
Manoukian S., Barile M., Genuardi M., Arnold N., Meindl A., Sutter
C., Wappenschmidt B., Domchek S.M., Pfeiler G., Friedman E.,
Jensen U.B., Robson M., Shah S., Lazaro C., Mai P.L., Benitez
J., Southey M.C., Schmidt M.K., Fasching P.A., Peto J., Humphreys M.K., Wang Q., Michailidou K., Sawyer E.J., Burwinkel B.,
Guénel P., Bojesen S.E., Milne R.L., Brenner H., Lochmann M.,
Brauch H., Ko Y.D., Baisch C., Fischer H.P., Bruening T., Pesch
B., Rabstein S., Spickenheuer A., Aittomäki K., Dörk T., Margolin
S., Mannermaa A., Lambrechts D., Chang-Claude J., Radice P.,
Giles G.G., Haiman C.A., Winqvist R., Devillee P., Garcia-Closas
M., Schoof N., Hooning M.J., Cox A., Pharoah P.D.P., Jakubowska
A., Orr N., Gonzalez-Neira A., Pita G., Alonso M.R., Hall P., Couch
F.J., Simard J., Altshuler D., Easton D.F., Chenevix-Trench G.,
Antoniou A.C., Offit K., Rookus M.A., van Leeuwen F.E., Verhoef S.,
de Lange J.L., Collée J.M., Seynaeve C., van Deurzen C.H.M., van
Asperen C.J., Tollenaar R.A., Devilee P., van Cronenburg T.C.T.E.,
Mensenkamp A.R., van der Luijt R.B., van Os T.A.M., Gille J.J.P.,
Waisfisz Q., Meijers-Heijboer H.E.J., Gomez-Garcia E.B., Blok
M.J., Oosterwijk J.C., Mourits M.J., de Bock G.H., Vasen H.F.,
Miedzybrodzka Z., Gregory H., Morrison P., Jeffers L., Cole T., Ong
K.R., Hoffman J., Donaldson A., James M., Paterson J., Taylor
A., Murray A., Rogers M.T., McCann E., Kennedy M.J., Barton
D., Porteous M., Drummond S., Brewer C., Kivuva E., Searle
A., Goodman S., Hill K., Davidson R., Murday V., Bradshaw N.,
Snadden L., Longmuir M., Watt C., Gibson S., Haque E., Tobias
E., Duncan A., Izatt L., Langman C., Brady A., Dorkins H., Melville
A., Randhawa K., Barwell J., Serra-Feliu G., Ellis I., Houghton C.,
Lalloo F., Taylor J., Side L., Male A., Berlin C., Eason J., Collier R.,
Douglas F., Claber O., Jobson I., Walker L., McLeod D., Halliday
D., Durell S., Stayner B., Eeles R.A., Shanley S., Rahman N.,
Houlston R., Bancroft E., Page E., Ardern-Jones A., Kohut K.,
Wiggins J., Castro E., Killick E., Martin S., Rea G., Kulkarni A.,
Cook J., Quarrell O., Bardsley C., Hodgson S., Goff S., Brice G.,
Winchester L., Eddy C., Tripathi V., Attard V., Lehmann A., Eccles
D., Lucassen A., Crawford G., McBride D., Smalley S., Sinilnikova
O., Verny-Pierre C., Giraud S., Léone M., and Gauthier-Villars
M. Identification of a BRCA2-Specific Modifier Locus at 6p24
Related to Breast Cancer Risk. [2013] PLoS Genetics (9) 3 :
e1003173-e1003173. Impact factor : 8.167
[188] Ferté C., Trister A.D., Huang E., Bot B.M., Guinney J., Commo F.,
Sieberts S., André F., Besse B., Soria J.C., and Friend S.H. Impact
of bioinformatic procedures in the development and translation
of high-throughput molecular classifiers in oncology. [2013]
Clinical Cancer Research (19) 16 : 4315-4325. Impact factor :
8.193
[189] Andre F., Dieci M.V., Dubsky P., Sotiriou C., Curigliano G., Denkert
C., and Loi S. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer.
[2013] Clinical Cancer Research (19) 1 : 28-33. Impact factor :
8.193
[190] André F., Bachelot T., Campone M., Dalenc F., Perez-Garcia J.M.,
Hurvitz S.A., Turner N., Rugo H., Smith J.W., Deudon S., Shi M.,
Zhang Y., Kay A., Porta D.G., Yovine A., and Baselga J. Targeting
FGFR with dovitinib (TKI258): preclinical and clinical data in
breast cancer. [2013] Clinical Cancer Research (19) 13 : 36933702. Impact factor : 8.193
[191] Angevin E., Lopez-Martin J.A., Lin C.C., Gschwend J.E., Harzstark
A., Castellano D., Soria J.C., Sen P., Chang J., Shi M., Kay A., and
Escudier B. Phase i study of dovitinib (TKI258), an oral FGFR,
VEGFR, and PDGFR inhibitor, in advanced or metastatic renal
cell carcinoma. [2013] Clinical Cancer Research (19) 5 : 12571268. Impact factor : 8.193
[192] Gini B., Zanca C., Guo D., Matsutani T., Masui K., Ikegami S.,
Yang H., Nathanson D., Villa G.R., Shackelford D., Zhu S., Tanaka
K., Babic I., Akhavan D., Lin K., Assuncao A., Gu Y., Bonetti B.,
Mortensen D.S., Xu S., Raymon H.K., Cavenee W.K., Furnari F.B.,
James C.D., Kroemer G., Heath J.R., Hege K., Chopra R., Cloughesy T.F., and Mischel P.S. The mTOR kinase inhibitors, CC214-1
and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. [2013] Clinical Cancer Research (19) 20 :
5722-5732. Impact factor : 8.193
[193] Italiano A., Lagarde P., Brulard C., Terrier P., Laë M., Marques B.,
Ranchere-Vince D., Michels J.J., Trassard M., Cioffi A., Piperno-Neumann S., Chevreau C., Blay J.Y., Delcambre C., Isambert
N., Penel N., Bay J.O., Bonvalot S., Le Cesne A., Coindre J.M., and
Chibon F. Genetic profiling identifies two classes of soft-tissue
leiomyosarcomas with distinct clinical characteristics. [2013]
Clinical Cancer Research (19) 5 : 1190-1196 . Impact factor : 8.193
[194] Malouf G.G., Monzon F.A., Couturier J., Molinié V., Escudier B.,
Camparo P., Su X., Yao H., Tamboli P., Lopez-Terrada D., Picken
M., Garcia M., Multani A.S., Pathak S., Wood C.G., and Tannir N.M.
Genomic heterogeneity of translocation renal cell carcinoma.
[2013] Clinical Cancer Research (19) 17 : 4673-4684. Impact
factor : 8.193
[195] Ott P.A., Hodi F.S., and Robert C. CTLA-4 and PD-1/PD-L1 blockade: New immunotherapeutic modalities with durable clinical
benefit in melanoma patients. [2013] Clinical Cancer Research
(19) 19 : 5300-5309. Impact factor : 8.193
[196] Robert C., Schadendorf D., Messina M., Hodi F.S., and O’Day S.
Efficacy and safety of retreatment with ipilimumab in patients
with pretreated advanced melanoma who progressed after initially achieving disease control. [2013] Clinical Cancer Research
(19) 8 : 2232-2239. Impact factor : 8.193
[197] Ryan C.J., Rosenthal M., Ng S., Alumkal J., Picus J., Gravis
G., Fizazi K., Forget F., Machiels J.P., Srinivas S., Zhu M., Tang
R., Oliner K.S., Jiang Y., Loh E., Dubey S., and Gerritsen W.R.
Targeted MET inhibition in castration-resistant prostate cancer:
A randomized phase II study and biomarker analysis with
rilotumumab plus mitoxantrone and prednisone. [2013] Clinical
Cancer Research (19) 1 : 215-224. Impact factor : 8.193
[198] Sessa C., LoRusso P., Tolcher A., Farace F., Lassau N., Delmonte
A., Braghetti A., Bahleda R., Cohen P., Hospitel M., VeyratFollet C., and Soria J.C. Phase I safety, pharmacokinetic and
pharmacodynamic evaluation of the vascular disrupting agent
ombrabulin (AVE8062) in patients with advanced solid tumors.
[2013] Clinical Cancer Research (19) 17 : 4832-4842. Impact
factor : 8.193
[199] Vassal G., Geoerger B., and Morland B. Is the European Pediatric
Medicine Regulation working for children and adolescents with
cancer? [2013] Clinical Cancer Research (19) 6 : 1315-1325.
[200] El Behi M., Krumeich S., Lodillinsky C., Kamoun A., Tibaldi L.,
Sugano G., De Reynies A., Chapeaublanc E., Laplanche A., Lebret
T., Allory Y., Radvanyi F., Lantz O., Eijan A.M., Bernard-Pierrot I.,
and Thery C. An essential role for decorin in bladder cancer invasiveness. [2013] EMBO Molecular Medicine (5) 12 : 1835-1851.
[201] Gallo V., Wark P.A., Jenab M., Pearce N., Brayne C., Vermeulen R.,
Andersen P.M., Hallmans G., Kyrozis A., Vanacore N., Vahdaninia
M., Grote V., Kaaks R., Mattiello A., Bas Bueno-De-mesquita H.,
Peeters P.H., Travis R.C., Petersson J., Hansson O., Arriola L.,
Martin J.M.J., Tjonneland A., Halkjaer J., Agnoli C., Sacerdote C.,
Bonet C., Trichopoulou A., Gavrila D., Overvad K., Weiderpass E.,
Palli D., Quiros J.R., Tumino R., Khaw K.T., Wareham N., Barricante-Gurrea A., Fedirko V., Ferrari P., Clavel-Chapelon F., Ruault
M.C.B., Boeing H., Vigl M., Middleton L., Riboli E., and Vineis P.
Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis: The EPIC cohort. [2013] Neurology (80) 9 : 829-838.
[202] Mathon B., Blauwblomme T., Bolle S., Dufour C., Nagarra O.,
Brunelle F., and Puget S. De novo arteriovenous malformation
after brain radiotherapy for medulloblastoma in a child. [2013]
Neurology (81) 4 : 398-399. Impact factor : 8.303
[203] Büttner S., Faes L., Reichelt W.N., Broeskamp F., Habernig L.,
Benke S., Kourtis N., Ruli D., Carmona-Gutierrez D., Eisenberg
T., D’hooge P., Ghillebert R., Franssens V., Harger A., Pieber
T.R., Freudenberger P., Kroemer G., Sigrist S.J., Winderickx J.,
Callewaert G., Tavernarakis N., and Madeo F. The Ca 2+/Mn
2+ ion-pump PMR1 links elevation of cytosolic Ca 2+ levels to
a-synuclein toxicity in Parkinson’s disease models. [2013] Cell
Death and Differentiation. Impact factor : 8.385
[204] Jemaa M., Galluzzi L., Kepp O., Senovilla L., Brands M., Boemer
U., Koppitz M., Lienau P., Prechtl S., Schulze V., Siemeister G.,
Wengner A.M., Mumberg D., Ziegelbauer K., Abrieu A., Castedo
M., Vitale I., and Kroemer G. Characterization of novel MPS1
inhibitors with preclinical anticancer activity. [2013] Cell Death
and Differentiation (20) 11 : 1532-1545. Impact factor : 8.385
[205] Ridinger-Saison M., Evanno E., Gallais I., Rimmelé P., Selimoglu-Buet D., Sapharikas E., Moreau-Gachelin F., and Guillouf
C. Epigenetic silencing of Bim transcription by Spi-1/PU.1
promotes apoptosis resistance in leukaemia. [2013] Cell Death
and Differentiation (20) 9 : 1268-1278. Impact factor : 8.385
[206] Villella V.R., Esposito S., Bruscia E.M., Vicinanza M., Cenci S.,
Guido S., Pettoello-Mantovani M., Carnuccio R., De Matteis
M.A., Luini A., Maiuri M.C., Raia V., Kroemer G., and Maiuri L.
Disease-relevant proteostasis regulation of cystic fibrosis
transmembrane conductance regulator. [2013] Cell Death and
Differentiation (20) 8 : 1101-1115. Impact factor : 8.385
[207] Fimia G.M., Kroemer G., and Piacentini M. Molecular mechanisms of selective autophagy. [2013] Cell Death and Differentiation (20) 1 : 1-2. Impact factor : 8.385
[208] Galluzzi L., Vacchelli E., Michels J., Garcia P., Kepp O., Senovilla
L., Vitale I., and Kroemer G. Effects of vitamin B6 metabolism
on oncogenesis, tumor progression and therapeutic responses.
[2013] Oncogene (32) 42 : 4995-5004. Impact factor : 8.559
[209] Vainchenker W. and Constantinescu S.N. JAK/STAT signaling in
hematological malignancies. [2013] Oncogene (32) 21 : 26012613. Impact factor : 8.559
[210] Lainey E., Wolfromm A., Marie N., Enot D., Scoazec M., Bouteloup
C., Leroy C., Micol J.B., De Botton S., Galluzzi L., Fenaux P., and
Kroemer G. Azacytidine and erlotinib exert synergistic effects
against acute myeloid leukemia. [2013] Oncogene. Impact
factor : 8.559
[211] Postel-Vinay S., Bajrami I., Friboulet L., Elliott R., Fontebasso
Y., Dorvault N., Olaussen K.A., André F., Soria J.C., Lord C.J.,
and Ashworth A. A high-throughput screen identifies PARP1/2
inhibitors as a potential therapy for ERCC1-deficient non-small
cell lung cancer. [2013] Oncogene (32) 47 : 5377-5387. Impact
factor : 8.559
[212] Yao Z., Jones A.W.E., Fassone E., Sweeney M.G., Lebiedzinska
M., Suski J.M., Wieckowski M.R., Tajeddine N., Hargreaves I.P.,
Yasukawa T., Tufo G., Brenner C., Kroemer G., Rahman S., and
Szabadkai G. PGC-1ß mediates adaptive chemoresistance associated with mitochondrial DNA mutations. [2013] Oncogene.
[213] Brand J.S., van der Schouw Y.T., Onland-Moret N.C., Sharp S.J.,
Ong K.K., Khaw K.T., Ardanaz E., Amiano P., Boeing H., Chirlaque
M.D., Clavel-Chapelon F., Crowe F.L., de Lauzon-Guillain B., Duell
E.J., Fagherazzi G., Franks P.W., Grioni S., Groop L.C., Kaaks
R., Key T.J., Nilsson P.M., Overvad K., Palli D., Panico S., Quiros
J.R., Rolandsson O., Sacerdote C., SÃ¡nchez M.a.J., Slimani N.,
Teucher B., Tjonneland A., Tumino R., van d.A., Feskens E.J.M.,
Langenberg C., Forouhi N.G., Riboli E., and Wareham N.J. Age
at menopause, reproductive life span, and type 2 diabetes risk:
results from the EPIC-InterAct study. [2013] Diabetes care (36)
4 : 1012-1019. Impact factor : 8.570
[214] Lajous M., Tondeur L., Fagherazzi G., De Lauzon-Guillain B.,
Boutron-Ruaualt M.C., and Clavel-Chapelon F. Childhood and
adult secondhand smoke and type 2 diabetes in women. [2013]
Diabetes care (36) 9 : 2720-2725. Impact factor : 8.570
[215] Zamora-Ros R., Forouhi N.G., Sharp S.J., Gonzalez C.A., Buijsse
B., Guevara M., van der Schouw Y.T., Amiano P., Boeing H., Bredsdorff L., Clavel-Chapelon F., Fagherazzi G., Feskens E.J., Franks
P.W., Grioni S., Katzke V., Key T.J., Khaw K.T., Kühn T., Masala G.,
Mattiello A., Molina-Montes E., Nilsson P.M., Overvad K., Perquier
F., Quiros J.R., Romieu I., Sacerdote C., Scalbert A., Schulze M.,
Slimani N., Spijkerman A.M.W., Tjonneland A., Tormo M.J., Tumino R., van d.A., Langenberg C., Riboli E., and Wareham N.J. The
association between dietary flavonoid and lignan intakes and
incident type 2 diabetes in European populations: the EPIC-InterAct study. [2013] Diabetes care (36) 12 : 3961-3970. Impact
factor : 8.570
[216] Daraï E., Fauvet R.L., Uzan C., Gouy S., Duvillard P., and Morice P.
Fertility and borderline ovarian tumor: A systematic review of
conservative management, risk of recurrence and alternative
options. [2013] Human Reproduction Update (19) 2 : 138-139.
[217] Bacquin A., Pouvelle C., Siaud N., Perderiset M., Salomé-Desnoulez S., Tellier-Lebegue C., Lopez B., Charbonnier J.B., and
Kannouche P.L. The helicase FBH1 is tightly regulated by PCNA
via CRL4(Cdt2)-mediated proteolysis in human cells. [2013]
Nucleic acids research (41) 13 : 6501-6513. Impact factor : 8.808
[218] Huret J.L., Ahmad M., Arsaban M., Bernheim A., Cigna J., Desangles F., Guignard J.C., Jacquemot-Perbal M.C., Labarussias M.,
Leberre V., Malo A., Morel-Pair C., Mossafa H., Potier J.C., Texier
G., Viguié F., Wan-Senon S.Y.C., Zasadzinski A., and Dessen P. Atlas of genetics and cytogenetics in oncology and haematology in
2013. [2013] Nucleic acids research (41) D1 : D920-D924. Impact
factor : 8.808
[219] Talhaoui I., Couvé S., Ishchenko A.A., Kunz C., Schär P., and Sapa-
rbaev M. 7,8-dihydro-8-oxoadenine, a highly mutagenic adduct,
is repaired by Escherichia coli and human mismatch-specific
uracil/thymine-DNA glycosylases. [2013] Nucleic acids research
(41) 2 : 912-923. Impact factor : 8.808
[220] Chargari C., Clemenson C., Martins I., Perfettini J.L., and Deutsch
E. Understanding the functions of tumor stroma in resistance to
ionizing radiation: Emerging targets for pharmacological modulation. [2013] Drug Resistance Updates (16) 1-2 : 10-21. Impact
factor : 8.816
[221] Pietrocola F., Izzo V., Niso-Santano M., Vacchelli E., Galluzzi
L., Maiuri M.C., and Kroemer G. Regulation of autophagy by
stress-responsive transcription factors. [2013] Seminars in
Cancer Biology (23) 5 : 310-322. Impact factor : 9.143
[222] Richard S., Gardie B., Couvé S., and Gad S. Von Hippel-Lindau:
How a rare disease illuminates cancer biology. [2013] Seminars
in Cancer Biology. Impact factor : 9.143
[223] Dossus L., Kvaskoff M., Bijon A., Engel P., Verdebout J., Fervers
B., Boutron-Ruault M.C., Clavel-Chapelon F., and Mesrine S. Latitude and ultraviolet radiation dose in the birthplace in relation
to menarcheal age in a large cohort of french women. [2013]
International Journal of Epidemiology (42) 2 : 590-600. Impact
factor : 9.197
[224] Akalay I., Janji B., Hasmim M., Noman M.Z., André F., De Cremoux P., Bertheau P., Badoual C., Vielh P., Larsen A.K., Sabbah
M., Tan T.Z., Keira J.H., Hung N.T.Y., Thiery J.P., Mami-Chouaib
F., and Chouaib S. Epithelial-to-mesenchymal transition and
autophagy induction in breast carcinoma promote escape from
t-cell-mediated lysis. [2013] Cancer Research (73) 8 : 24182427. Impact factor : 9.284
[225] Casetti L., Martin-Lannerée S., Najjar I., Plo I., Augé S., Roy L.,
Chomel J.C., Lauret E., Turhan A.G., and Dusanter-Fourt I. Differential contributions of STAT5A and STAT5B to stress protection
and tyrosine kinase inhibitor resistance of chronic myeloid
leukemia stem/progenitor cells. [2013] Cancer Research (73) 7 :
2052-2058. Impact factor : 9.284
[226] Chantöme A., Potier-Cartereau M., Clarysse L., Fromont G., Marionneau-Lambot S., Guéguinou M., Pagés J.C., Collin C., Oullier T.,
Girault A., Arbion F., Haelters J.P., Jaffré P.A., Pinault M., Besson
P., Joulin V., Bougnoux P., and Vandier C. Pivotal role of the lipid
raft SK3-orai1 complex in human cancer cell migration and
bone metastases. [2013] Cancer Research (73) 15 : 4852-4861.
[227] Franciszkiewicz K., Le Floc’h A., Boutet M., Vergnon I., Schmitt
A., and Mami-Chouaib F. CD103 or LFA-1 engagement at the
immune synapse between cytotoxic T cells and tumor cells
promotes maturation and regulates T-cell effector functions.
[2013] Cancer Research (73) 2 : 617-628. Impact factor : 9.284
[228] Goéré D., Flament C., Rusakiewicz S., Poirier-Colame V., Kepp
O., Martins I., Pesquet J., Eggermont A., Elias D., Chaput N., and
Zitvogel L. Potent immunomodulatory effects of the trifunctional
antibody catumaxomab. [2013] Cancer Research (73) 15 : 46634673. Impact factor : 9.284
[229] Laderach D.J., Gentilini L.D., Giribaldi L., Delgado V.C., Nugnes
L., Croci D.O., Al Nakouzi N., Sacca P., Casas G., Mazza O., Shipp
M.A., Vazquez E., Chauchereau A., Kutok J.L., Rodig S.J., Elola
M.T., Compagno D., and Rabinovich G.A. A unique galectin signature in human prostate cancer progression suggests galectin-1
as a key target for treatment of advanced disease. [2013] Cancer
Research (73) 1 : 86-96. Impact factor : 9.284
[230] Michels J., Vitale I., Galluzzi L., Adam J., Olaussen K.A., Kepp O.,
Senovilla L., Talhaoui I., Guegan J., Enot D.P., Talbot M., Robin
A., Girard P., Orear C., Lissa D., Sukkurwala A.Q., Garcia P.,
Behnam-Motlagh P., Kohno K., Wu G.S., Brenner C., Dessen P.,
Saparbaev M., Soria J.C., Castedo M., and Kroemer G. Cisplatin
resistance associated with PARP hyperactivation. [2013] Cancer
[231] Molina A., Velot L., Ghouinem L., Abdelkarim M., Bouchet B.P.,
Luissint A.C., Bouhlel I., Morel M., Sapharikas E., Di Tommaso A.,
Honoré S., Braguer D., Gruel N., Vincent-Salomon A., Delattre O.,
Sigal-Zafrani B., André F., Terris B., Akhmanova A., Di Benedetto
M., Nahmias C., and Rodrigues-Ferreira S. ATIP3, a novel prognostic marker of breast cancer patient survival, limits cancer
cell migration and slows metastatic progression by regulating
microtubule dynamics. [2013] Cancer Research (73) 9 : 29052915. Impact factor : 9.284
232. Quidville V., Alsafadi S., Goubar A., Commo F., Scott V., Pioche-Durieu C., Girault I., Baconnais S., Le Cam E., Lazar V.,
Delaloge S., Saghatchian M., Pautier P., Morice P., Dessen P.,
Vagner S., and Andre F. Targeting the deregulated spliceosome
core machinery in cancer cells triggers mTOR blockade and
autophagy. [2013] Cancer Research (73) 7 : 2247-2258. Impact
factor : 9.284
[233] Rusakiewicz S., Semeraro M., Sarabi M., Desbois M., Locher
C., Mendez R., Vimond N., Concha A., Garrido F., Isambert N.,
Chaigneau L., Le Brun-Ly V., Dubreuil P., Cremer I., Caignard A.,
Poirier-Colame V., Chaba K., Flament C., Halama N., JagÌˆer D.,
Eggermont A., Bonvalot S., Commo F., Terrier P., Opolon P., Emile
J.F., Coindre J.M., Kroemer G., Chaput N., Le Cesne A., Blay
J.Y., and Zitvogel L. Immune infiltrates are prognostic factors
in localized gastrointestinal stromal tumors. [2013] Cancer
[234] Marty C., Lacout C., Droin N., Le Couédic J.P., Ribrag V., Solary E.,
Vainchenker W., Villeval J.L., and Plo I. A role for reactive oxygen
species in JAK2 V617F myeloproliferative neoplasm progression. [2013] Leukemia (27) 11 : 2187-2195. Impact factor : 9.379
[235] Itzykson R. and Solary E. An evolutionary perspective on chronic
myelomonocytic leukemia. [2013] Leukemia (27) 7 : 1441-1450.
[236] Vainchenker W. and Favale F. Myelofibrosis, JAK2 inhibitors and
erythropoiesis. [2013] Leukemia (27) 6 : 1219-1223. Impact
factor : 9.379
[237] Damm F., Itzykson R., Kosmider O., Droin N., Renneville A.,
Chesnais V., Gelsi-Boyer V., De Botton S., Vey N., Preudhomme C.,
Clavert A., Delabesse E., Park S., Birnbaum D., Fontenay M., Bernard O.A., and Solary E. SETBP1 mutations in 658 patients with
myelodysplastic syndromes, chronic myelomonocytic leukemia
and secondary acute myeloid leukemias. [2013] Leukemia (27)
6 : 1401-1403. Impact factor : 9.379
[238] Kosmider O., Itzykson R., Chesnais V., Lasho T., Laborde R.,
Knudson R., Gauthier A., Merlevede J., Ades L., Morabito M.,
Fontenay M., Tefferi A., Droin N., and Solary E. Mutation of the
colony-stimulating factor-3 receptor gene is a rare event with
poor prognosis in chronic myelomonocytic leukemia. [2013]
Leukemia (27) 9 : 1946-1949. Impact factor : 9.379
[239] Schmidt M., Sonneville R., Schnell D., Bigé N., Hamidfar R., Mongardon N., Castelain V., Razazi K., Marty A., Vincent F., Dres M.,
Gaudry S., Luyt C.E., Das V., Micol J.B., Demoule A., and Mayaux
J. Clinical features and outcomes in patients with disseminated
toxoplasmosis admitted to intensive care: A multicenter study.
[2013] Clinical Infectious Diseases (57) 11 : 1535-1541. Impact
factor : 9.416
[240] Bergoglio V., Boyer A.S., Walsh E., Naim V., Legube G., Lee
M.Y.W.T., Rey L., Rosselli F., Cazaux C., Eckert K.A., and Hoffmann
J.S. DNA synthesis by pol n promotes fragile site stability by
preventing under-replicated DNA in mitosis. [2013] Journal of
Cell Biology (201) 3 : 395-408. Impact factor : 9.688
[241] Chen Y., Aardema J., Kale S., Whichard Z.L., Awomolo A.,
Blanchard E., Chang B., Myers D.R., Ju L., Tran R., Reece D.,
Christensen H., Boukour S., Debili N., Strom T.S., Rawlings D.,
Vazquez F.X., Voth G.A., Zhu C., Kahr W.H.A., Lam W.A., and Corey
S.J. Loss of the F-BAR protein CIP4 reduces platelet production
by impairing membrane-cytoskeleton remodeling. [2013] Blood
(122) 10 : 1695-1706. Impact factor : 9.775
[242] Damm F., Chesnais V., Nagata Y., Yoshida K., Scourzic L.,
Okuno Y., Itzykson R., Sanada M., Shiraishi Y., Gelsi-Boyer V.,
Renneville A., Miyano S., Mori H., Shih L.Y., Park S., Dreyfus F.,
Guerci-Bresler A., Solary E., Rose C., Cheze S., Prébet T., Vey N.,
Legentil M., Duffourd Y., Botton S.D., Preudhomme C., Birnbaum
D., Bernard O.A., Ogawa S., Fontenay M., and Kosmider O. BCOR
and BCORL1 mutations in myelodysplastic syndromes and
related disorders. [2013] Blood (122) 18 : 3169-3177. Impact
factor : 9.775
[243] Delarue R., Haioun C., Ribrag V., Brice P., Delmer A., Tilly H.,
Salles G., Van Hoof A., Casasnovas O., Brousse N., Lefrere F.,
and Hermine O. CHOP and DHAP plus rituximab followed by
autologous stem cell transplantation in mantle cell lymphoma:
A phase 2 study from the Groupe d’Etude des Lymphomes de
l’Adulte. [2013] Blood (121) 1 : 48-53. Impact factor : 9.775
[244] Gerrard M., Waxman I.M., Sposto R., Aupérin A., Perkins S.L.,
Goldman S., Harrison L., Pinkerton R., McCarthy K., Raphael M.,
Patte C., and Cairo M.S. Outcome and pathologic classification
of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy. [2013]
Blood (121) 2 : 278-285. Impact factor : 9.775
[245] Hasan S., Lacout C., Marty C., Cuingnet M., Solary E., Vainchenker W., and Villeval J.L. JAK2V617F expression in mice amplifies
early hematopoietic cells and gives them a competitive advantage that is hampered by IFNa. [2013] Blood (122) 8 : 1464-1477.
[246] Itzykson R., Kosmider O., Renneville A., Morabito M., Preudhomme C., Berthon C., Ades L., Fenaux P., Platzbecker U., Gagey
O., Rameau P., Meurice G., Orear C., Delhommeau F., Bernard
O.A., Fontenay M., Vainchenker W., Droin N., and Solary E. Clonal
architecture of chronic myelomonocytic leukemias. [2013] Blood
(121) 12 : 2186-2198. Impact factor : 9.775
[247] Malinge S., Thiollier C., Chlon T.M., Doré L.C., Diebold L., Bluteau
O., Mabialah V., Vainchenker W., Dessen P., Winandy S., Mercher
T., and Crispino J.D. Ikaros inhibits megakaryopoiesis through
functional interaction with GATA-1 and NOTCH signaling. [2013]
Blood (121) 13 : 2440-2451. Impact factor : 9.775
[248] Pleines I., Dütting S., Cherpokova D., Eckly A., Meyer I., Morowski
M., Krohne G., Schulze H., Gachet C., Debili N., Brakebusch C.,
and Nieswandt B. Defective tubulin organization and proplatelet
formation in murine megakaryocytes lacking Rac1 and Cdc42.
[2013] Blood (122) 18 : 3178-3187. Impact factor : 9.775
[249] Roux C., Nicolini F.E., Rea D., Niault M., Mollica L., Berger F.,
Chassagne-Clément C., Tigaud I., Tulliez M., Giraudier S., Turhan
A., Rousselot P., and Legros L. Reversible lymph node follicular
hyperplasia associated with dasatinib treatment of chronic
myeloid leukemia in chronic phase. [2013] Blood (122) 17 : 30823084. Impact factor : 9.775
[250] Allouch A., David A., Amie S.M., Lahouassa H., Chartier L., Margottin-Goguet F., Barré-Sinoussi F., Kim B., Saez-Cirion A., and
Pancino G. P21-mediated RNR2 repression restricts HIV-1 replication in macrophages by inhibiting dNTP biosynthesis pathway.
[2013] Proceedings of the National Academy of Sciences of the
United States of America (110) 42 : E3997-E4006. Impact factor :
9.809
[251] Baginska J., Viry E., Berchem G., Poli A., Noman M.Z., Van Moer
K., Medves S., Zimmer J., Oudin A., Niclou S.P., Bleackley R.C.,
Goping I.S., Chouaib S., and Janji B. Granzyme B degradation
by autophagy decreases tumor cell susceptibility to natural
killer-mediated lysis under hypoxia. [2013] Proceedings of the
National Academy of Sciences of the United States of America
(110) 43 : 17450-17455. Impact factor : 9.809
[252] Cornelis G., Heidmann O., Degrelle S.A., Vernochet C., Lavialle
C., Letzelter C., Bernard-Stoecklin S., Hassanin A., Mulot B.,
Guillomot M., Hue I., Heidmann T., and Dupressoir A. Captured
retroviral envelope syncytin gene associated with the unique
placental structure of higher ruminants. [2013] Proceedings
of the National Academy of Sciences of the United States of
America (110) 9 : E828-E837. Impact factor : 9.809
[253] Mazouzi A., Vigouroux A., Aikeshev B., Brooks P.J., Saparbaev
M.K., Morera S., and Ishchenko A.A. Insight into mechanisms of
3’-5’ exonuclease activity and removal of bulky 8,5’-cyclopurine
adducts by apurinic/apyrimidinic endonucleases. [2013]
Proceedings of the National Academy of Sciences of the United
States of America (110) 33 : E3071-E3080. Impact factor : 9.809
[254] Prorok P., Alili D., Saint-Pierre C., Gasparutto D., Zharkov D.O.,
Ishchenko A.A., Tudek B., and Saparbaev M.K. Uracil in duplex
DNA is a substrate for the nucleotide incision repair pathway
in human cells. [2013] Proceedings of the National Academy of
Sciences of the United States of America (110) 39 : E3695-E3703.
Retouvez la liste des publications
à Impact Factor entre 10 et 20
et supérieur à 20 dans l’espace
rapports annuels du site internet
de Gustave Roussy

Annual report 2013

Transcription

Documents pareils

Eye Wear Safety Instructions

rapport annuel - les annexes

rapport annuel 2015

HemosIL - Werfen

Jean-Louis Pujol, MD, Ph.D, Psy.D. Head of Montpellier

HemosIL™ Factor X deficient plasma

VisuLize-FIX Antigen Kit for ELISA

SPMSD Interactions with Patient Organizations in 2014

1978

Celebrity names of pancreatic cancer

Dissertation Tabea Appel (Medizin)